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 There are few studies on the risk factors of primary congenital glaucoma (PCG) and 
anterior segment defects (ASDs) of the eye in a US-based population. The goal of this 
dissertation was to evaluate maternal diet, a modifiable risk factor, and to explore genes which 
have not previously been evaluated within PCG cases. Each of these exposures were evaluated 
within the National Birth Defects Prevention Study (NBDPS), a large population-based case-
control study in the United States. Specific Aim 1 evaluated maternal diet through intake levels 
of individual micronutrients, a diet quality score, and the creation and evaluation of dietary 
patterns. Inverse, albeit imprecise, associations were seen for a number of individual 
micronutrients. Diet quality did not appear to be associated with having a child with PCG or 
ASDs. Mothers who adhered to the Prudent and Mexican dietary patterns appeared to have lower 
odds of having a child with these defects. In Specific Aim 2, samples from a subset of PCG cases 
from the NBDPS underwent whole-exome sequencing. The goal of this aim was to identify rare 
mutations in genes which previously have not been investigated in relation to PCG. We found a 
similar proportion (13.5%) of families with variants in CYP1B1, the most commonly mutated 
gene in PCG. In addition, we found a number of variants present in individual families which 
occurred in genes that are known to underly other Mendelian conditions, some with phenotypic 
iv 
 
overlap, or genes which are known to play a role in eye development signaling pathways. These 
genes, and specific variants, should be further explored through in vitro, in vivo, and other 
epidemiologic studies to better understand the genetic mechanisms in PCG cases. The findings of 
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CHAPTER 1 – INTRODUCTION AND SPECIFIC AIMS 
Congenital glaucoma encompasses both primary congenital glaucoma (PCG) and related 
defects of the anterior segment (ASDs) of the eye. By definition, PCG affects children younger 
than four with approximately 80% of cases being diagnosed before a child’s first birthday1. In the 
United States the prevalence rate of PCG is approximately 1 in 10,000 live births per year2,3, but 
is higher in cultures where inbreeding (consanguinity) is common3. Children present with raised 
intraocular pressure (IOP), loss of corneal transparency, photophobia, and buphthalmos 
(enlargement of the eyeball)2. PCG results in blindness in approximately 10% of cases and reduced 
vision in approximately half of all cases4. ASDs are a collection of developmental disorders which 
affect structures in anterior segment of the eye which include the iris, cornea, and trabecular 
meshwork5. Due to structural changes in the eye, children with some ASDs are at an increased risk 
of developing glaucoma. Prevalence rates of individual ASDs are even more rare than PCG with 
rates ranging from 1 in 64,000 (aniridia) to 1 in 200,000 (Axenfeld-Rieger Syndrome)6. 
Much of the work on risk factors for congenital glaucoma has focused on genetics and 
molecular factors, however the etiology remains only partially understood. Linkage studies of 
large, multigenerational families were used to identify areas of interest within the genome. The 
two genes identified include Cytochrome P450 Family 1 Subfamily B Member 1 (CYP1B1)7 and 
Latent transforming growth factor -binding protein 2 (LTBP2)8. Mutations in the CYP1B1 gene 
are thought to be the most common cause of congenital glaucoma worldwide7. There is biological 
plausibility for this because CYP1B1 plays an important role in elimination of reactive oxidative 




tissue responsible for draining the aqueous humor from the base of the eye. Defects in CYP1B1 
result in difficulties in achieving intraocular pressure control, a common risk factor for glaucoma. 
Mutations in this gene have been reported in 90-100% cases of Slovakian Roma Gypsies, 44%  of 
cases from India, and 50% of cases from Brazil9,10. Mutations in LTBP2, the second locus of 
interest identified through linkage studies, were identified in cases from Pakistani families and 
cases of Gypsy descent8,11.  Despite strong evidence pointing towards these two genes being 
causal, the generalizability of these findings remains uncertain. For example, mutations in CYP1B1 
are only present in 14.6% of affected individuals from the United States10, a more ethnically 
diverse population than the original families studied from Pakistani and of Gypsy descent. 
Additionally, PCG is generally thought to be transmitted as an autosomal-recessive trait with 
variable penetrance4-8, however, this model has been challenged with reports of transmission in 
successive generations, unequal sex distribution among affected individuals, and lower-than-
expected number of affected siblings in familial cases3,6-7,9-11. Reduced penetrance has been 
reported in certain families, suggesting existence of a modifier, or modifiers, located elsewhere in 
the genome12,14.   
Moreover, very little work has been done on modifiable risk factors of congenital 
glaucoma. Diet has been previously implicated in abnormal development of the eye. Several 
nutrients such as folic acid, vitamin D, and omega-3 fatty acids have been shown to produce fetal 
abnormalities, including malformations of the eye, neural tube, orofacial clefts, and heart12–17. 
Other nutrients like zinc, vitamin E and vitamin A have been identified for their contribution to 
eye development18–20. Additionally, animal studies have shown that mice with CYP1B1 mutations 
show similar phenotypes to children with primary congenital glaucoma including irregular 




oxidative stress21. The animal studies showed that the structural abnormalities in the trabecular 
meshwork could be prevented with the administration of the free radical scavenger N-
acetylcysteine21. This suggests that other molecules which act as free radical scavengers or have 
anti-oxidant capacities may have the ability to modify PCG risk.  
Despite the focus on specific genetic loci as a risk factor for PCG and ASDs, there is still 
a general lack of epidemiologic data on these defects in a non-selected (non-familial) group. 
Therefore, the National Birth Defects Prevention Study (NBDPS) provides an excellent 
population-based study sample to explore potential genetic and non-genetic risk factors.  
The purpose of this study is to address the gaps in the literature on the etiology of PGC and 
related ASDs through the following aims:  
Aim 1: Evaluate maternal nutrition as a risk factor for PCG and ASDs. A comprehensive 
approach will be taken to determine whether maternal nutrition is a risk factor for PCG and ASDs. 
To begin, intake of individual micronutrients will be compared between cases and controls to 
determine whether higher intake is associated with reduced risk. Second, the quality of maternal 
diets will be calculated with Diet Quality Index for Pregnancy (DQI-P) scores based on self-
reported diet in the NBDPS telephone interview22. These scores will be split into quartiles based 
on distribution in controls to determine whether those with poor diets are at an increased risk for 
giving birth to children with these birth defects. Finally, latent class analysis (LCA)23 will be used 
to classify women into dietary patterns to determine whether specific patterns are associated with 
an increased risk of giving birth to children with these birth defects.  
Aim 2:  Comprehensively investigate genetic variation in whole-exome sequencing data of a 
large cohort of nationally-representative cases of PCG in the United States. Much is known 




common, however studies in the United States have failed to find these same causal variants 
suggesting that alternate variants or mechanisms likely underlie cases from the United States. We 
plan to utilize the strengths of whole-exome sequencing data of family trios to describe rare, 
pathogenic mutations in genes which previously have not been investigated for PCG focusing on 






CHAPTER 2. - BACKGROUND 
2.1 Development of the eye and associated structures 
2.1.1 Early embryology 
The human eye is derived from various embryonic tissues including the neural ectoderm, 
surface ectoderm, and mesenchymal cells predominantly arising from neural crest cells. The eyes 
first appear in the fourth week as a pair of lateral grooves which evaginate out from the neural 
groove24 (Figure 2.1, A). These outpocketings grow out towards the surface ectoderm until only a 
few mesenchymal cells separate them from the surface ectoderm24. The surface ectoderm near the 
optic vesicles thickens to form the lens placode (Figure 2.1, A). Almost as soon as it appears, it 
invaginates until it pinches off and becomes a hollow lens vesicle24 (Figure 2.1, B). Around day 
32, the outermost layer of cells of the optic vesicles invaginate to form a goblet-shaped optic cup24 
(Figure 2.1, B). In the 6th week of development mesenchymal cells begin to migrate to the space 
between the anterior epithelium of the lens vesicle and the surface ectoderm.2 These cells then 
condense into a dense layer which later gives rise to the corneal endothelium. In the seventh week 
the mesenchyme surrounding the lens splits into two layers to encloses a new cavity which 
becomes the anterior chamber of the eye2,24. The thick posterior wall of the anterior chamber breaks 
down to create the posterior chamber and eventually forms an opening called the pupil24 (Figure 
2.1, E). By the end of the third month the cells in the choroid tissue differentiate into the iris24. As 




extracellular fibers to form the trabecular meshwork near the edge of the cornea (Figure 2.2 and 
2.3).  
 
Figure 2.1. Developmental stages of fetal eye development.  
2.1.2 Aqueous humor flow 
The aqueous humor is a clear fluid which flows from the posterior chamber to the anterior 
chamber and out of the eye through the trabecular meshwork and into the canal of Schlemm (see 
Figure 2.2)25,26. The eye is avascular, so adequate flow is necessary to supply nutrients and remove 
metabolic waste26. The amount of aqueous humor produced by the ciliary body in the eye must be 
equal to the amount of aqueous humor leaving the eye to maintain normal intraocular pressure 
(IOP)26. 
 Studies in both primates and humans have shown that increased IOP is closely linked to 
the death of retinal ganglion cells27,28 which are the cells that take information from the visual field 
to the brain. An exact mechanism for this death is not yet elucidated, however possible candidates 
include strain on the extracellular components surrounding these cells28 or through signaling 




glaucoma patients30. In fact, the only proven methods to treat glaucoma to date focus on reducing 
IOP31.   
 
Figure 2.2. Diagram of (2A) normal aqueous fluid flow and (2B) disrupted aqueous fluid flow 
found in glaucoma. Borrowed from Karmel M. Glaucoma Pipeline Drugs: Targeting the 




Figure 2.3. Complexity of the trabecular meshwork. Each color represents a different layer of the 
trabecular meshwork and the black arrow denotes the aqueous fluid flow. Adapted from Karmel 







2.2 Congenital Glaucoma 
Primary congenital glaucoma (PCG) cases are diagnosed early in childhood and develop 
without overt structural eye defects6. In the past, glaucoma that developed secondary to 
recognizable ocular or systemic findings were called “developmental glaucoma”, however new 
terminology is moving towards more unambiguous categories that can be seen in Table 2.1. The 
flow-chart in Figure 2.1 shows the decision tree physicians use to classify glaucoma in children. 
In this study, we plan to focus on cases of PCG and cases specific to the anterior segment including 
Peters anomaly, Axenfeld-Rieger anomaly, aniridia, and lens coloboma. These defects fit into the 
category of glaucoma associated with non-acquired ocular anomalies in Table 2.1. Because we are 
only including four of the conditions which fit into this category, we have decided to refer to them 
as anterior segment defects instead of the collective category name throughout the rest of this 
report.  
Table 2.1. Diagnostic Criteria for types of congenital glaucoma included in this study according 
to the Childhood Glaucoma Research Network (CGRN).  
Congenital Glaucoma Diagnostic Criteria 
Primary Congenital Glaucoma (PCG)  Isolated angle anomalies (+/- mild 
congenital iris anomalies)  
 Meets glaucoma definition (usually with 
ocular enlargement)  
 Subcategories based on age of onset  
(1) Neonatal or newborn onset (0-1    
month)  
(2) Infantile onset (>1-24 months)  
(3) Late onset or late-recognized (>2  
years)  
 Spontaneously arrested cases with 
normal IOP but typical signs of PCG 





Glaucoma Associated with Non-Acquired 
Ocular Anomalies  
 
 Includes conditions of predominantly 
ocular anomalies present at birth which 
may or may not be associated with 
systemic signs 
 Meets glaucoma definition  
 List common ocular anomalies: 
      Axenfeld Rieger anomaly (Syndrome if 
          systemic associations) 
      Peters anomaly (Syndrome if systemic 
          associations) 
      Ectropion uveae 
      Congenital iris hypoplasia 
      Aniridia 
      Persistent fetal vasculature/PFV (if 
         glaucoma present before cataract surgery) 
     Oculodermal melanocytosis (Nevus of Ota)   
     Posterior polymorphous dystrophy 
    Microphthalmos 
    Microcornea 
    Ectopia lentis 
        Simple ectopia lentis (no systemic 
           associations, possible Type 1 FBN 
           mutation)  








Figure 2.4. Childhood Glaucoma Research Network Classification System of childhood 
glaucoma.  
 
2.2.1 Primary congenital glaucoma descriptive epidemiology 
2.2.1.1 Clinical characteristics  
 Primary congenital glaucoma can be classified into three subtypes: neonatal or newborn, 
infantile, or late-onset. Neonatal or newborn cases of PCG are diagnosed within the first month of 
life. Infantile cases are diagnosed from the first month to two years of age and late-onset are those 




months of age2. Approximately 25% of infants with PCG and related defects are diagnosed at birth, 
and more than 80% are diagnosed within the first year of life1. These defects are usually bilateral 
(65-80%). 
 Children with PCG present with raised IOP, loss of corneal transparency, photophobia, and 
buphthalmos2. It results in blindness in approximately 10% of cases and reduced vision in 
approximately half of all cases2. Children are treated with IOP-lowering medications and angle 
surgery33. Management of the disease is more complicated than in adults due to differences in 
anatomy which are compounded by additional anatomic variations due to congenital anomalies, a 
more aggressive healing response, and a less predictable postoperative course33.    
2.2.1.2 Prevalence and mortality in the United States  
 Primary congenital glaucoma occurs in approximately 1 in 10,000 live births in Western 
countries, with increased rates being seen in populations with higher rates of consanguinity34. By 
definition, PCG affects children younger than four with approximately 80% of cases being 
diagnosed before a child turns one1. For a general ophthalmologist practicing in a non-specialist 
center in North America, this corresponds to diagnosing a new case once every 5 years35. There 
appears to be no racial or geographic predilection36. In the United States, boys are more commonly 
affected than girls at a ratio of 3:22,37.  
 Congenital glaucoma can lead to irreversible vision loss and is not thought of as a fatal 
disease27. Instead, the goal of both medical and surgical management is often to prevent further 
deterioration36. Children with these defects are generally identified early in life and benefit from 
advances in new instrumentation to measure intraocular pressure and visual field defects38. In 
addition to surgery, children will often be treated with medical therapies which are usually well 




2.2.1.3 Prevalence and mortality outside of the United States 
 There is minimal data on the incidence of primary congenital glaucoma in the developing 
world. Reports from sub-Saharan regions of Africa indicate that congenital glaucoma may account 
for 0.7-4% of all new glaucoma cases35,40–42. Primary congenital glaucoma is far more frequent in 
certain ethnic and religious groups where consanguineous relationships are common. In Saudi 
Arabia the prevalence is reported to be 1 in 2,500 live births and is even higher (1 in 1,200) in 
Gypsies in Slovakia43. 
 The limited resources and lack of experienced medical personnel in the developing world 
also have impacts on the care and management of affected individuals. In the United States, 
affected children are often diagnosed within the first few months of life, but in remote places like 
rural Ethiopia, one research team found the average age of diagnosis to be over 3 years of age35. 
Additionally, management of primary congenital glaucoma has significantly lower success rates 
in these countries when compared to those that are more developed 35. There are no long term 
follow-up studies of primary congenital glaucoma in the developing world35, but the life 
expectancy of a child with primary congenital glaucoma is likely lower due to the fact that 
blindness is closely linked to survival38. 
2.2.2 Anterior segment dysgenesis 
 Anterior chamber dysgenesis refers to a collection of developmental disorders which affect 
structures in the anterior segment of the eye which include the iris, cornea, and trabecular 
meshwork5. These disorders can refer to isolated ocular anomalies or a part of systemic defects 
which are characterized by both autosomal dominant and autosomal recessive patterns of 




 Glaucoma that occurs as a result of the structural defects is common, although not always 
present, in individuals with anterior segment defects. This project includes some individuals who 
have been diagnosed with anterior segment defects either with, or without, glaucoma. This next 
section will define the types of anterior segment defects that are included in our study sample.  
2.2.2.1 Peters anomaly 
 Peters anomaly is a heterogeneous set of disorders and is associated with a range of ocular 
abnormalities and varying amounts of corneal opacification5. There is very little published 
information about the incidence of Peters anomaly in the literature. A study published in 2014 by 
Kurilec and Zaidman extrapolated data from New York to estimate an incidence of 1.1-1.5 per 
100,000 births in the United States45. Both autosomal dominant and autosomal recessive 
inheritance patterns have been described46,47. Similar to Axenfeld-Rieger syndrome, which will be 
described in the next section, approximately 50% of patients with Peters anomaly will develop 
glaucoma5.  
 A number of mutations have been linked to Peters anomaly including in Paired box 6 
(PAX6)46, Forkhead box C1 (FOXC1)48,49, Paired like homeodomain 2 (PITX2)49, and 
CYP1B150,51.  
2.2.2.2 Axenfeld-Rieger Syndrome 
 Axenfeld-Rieger Syndrome is a heterogeneous group of disorders characterized by ocular 
and systemic features6. It is an extremely rare disease with a prevalence of approximately 
1:200,000 and is inherited in an autosomal dominant pattern with high penetrance and variable 
expressivity52. A number of structural ocular anomalies, all which can restrict fluid drainage from 




microscopic abnormalities of the trabecular meshwork6. Consequently, as many as 50% of 
Axenfeld-Rieger Syndrome patients develop elevated intraocular pressure and glaucoma53,54.   
 The CYP1B1 gene has been linked to Axenfeld-Rieger syndrome51, but linkage analyses 
have also identified two other genes: PITX2 and FOXC155.  
2.2.2.3 Aniridia 
 Aniridia translates to absence of the iris, although all patients affected by this disorder have 
at least some iris tissue6. The prevalence of this ocular disease is between 1/64,000 to 1/96,000. 
Both autosomal dominant and sporadic occurrences have been identified. It is thought that the 
secondary glaucoma in these patients results from the abnormal irises collapsing against the cornea 
and obstructing outflow of the aqueous humor resulting in increased intraocular pressure6.  
 Phenotypes similar to aniridia have been found in animal models where mutations occur in 
the common ancestor of the PAX6 gene56,57, a gene that is highly conserved and central to ocular 
development58. Sporadic cases are thought to be caused by a large deletion of chromosome 11p13 
which covers the PAX6 gene and occasionally also includes a deletion of the neighboring gene6.      
2.2.2.4 Lens coloboma 
 Colobomas are missing pieces of tissue resulting from defects in closure of fetal tissue59. 
They can occur in the lens, iris, ciliary body, choroid, and optic nerve60. The size and shape of 
colobomas in the lens can vary, but is characterized by notching of the equator of the lens61. 
Occasionally lens coloboma can appear in combination with other ocular defects59,61, but may also 
be manifestations of systemic diseases62,63. The literature on lens coloboma is extremely sparse 





2.3 Risk Factors of primary and congenital glaucoma and anterior chamber defects 
2.3.1. Genetic exposures  
 Much of the research on primary congenital glaucoma and anterior segment defects have 
focused on the genetics of the defects. Primary congenital glaucoma is familial in 10-40% of 
cases39. PCG is most often seen in families where consanguinity is present. In these families, cases 
are most often seen among siblings and in some families. High rates of concordance have been 
seen among monozygotic twins and discordant among dizygotic twins64–68. Primary congenital 
glaucoma is generally inherited as an autosomal recessive trait with variable expression and 
penetrance that ranges from 40-100%69, meaning that not everyone with the mutation presents with 
disease or presents in the same way. However, this model of inheritance has been challenged with 
reports of transmission in successive generations, unequal sex distribution among affected 
individuals, and lower-than-expected number of affected siblings in familial cases64,67,68,70–72. 
 Primary congenital glaucoma has been mapped to three loci within the genome: GLC3A73, 
GLC3B74, and GLC3C75. In 1995, Sarfarazi et al mapped GLC3A to a 2.5 centimorgan (cM) 
location on the 21st position on the p-arm of chromosome 2 (labeled: 2p21)73. The causative gene 
in this region was later found to be Cytochrome P450 Family 1 Subfamily B Member 1, or 
CYP1B1. The second primary congenital glaucoma site, GLCA3B, was mapped to a 3 cM location 
at chromosomal location 1p3674. This location within the genome has been implicated in malignant 
diseases and shown to frequently participate in recombination events74. The final primary 





2.3.1.1 Cytochrome P450 Family 1 Subfamily B Member 1 (CYP1B1) 
 CYP1B1 is a gene that encodes for a member of the cytochrome P450 family of enzymes 
which are known for their metabolic abilities76. In particular, the CYP1B1 protein is known to 
function in the metabolism of potentially toxic foreign compounds but is also known to metabolize 
endogenous compounds like retinoids. In normal eye development, CYP1B1 protein is expressed 
in the ciliary body, the non-pigmented epithelium, the iris, and the trabecular meshwork77. In fact, 
CYP1B1 null mice exhibit abnormalities in the trabecular meshwork and ocular drainage 
structures78. 
 In the Human Gene Mutation Database79, an online database of published germline 
mutations that underlie or are closely associated with human inherited disease, there are a total of 
148 mutations in CY1B1 which have been linked to primary congenital glaucoma80. Mutations in 
CYP1B1 are inherited in an autosomal recessive pattern and include missense and nonsense 
mutations, duplications, insertions, and deletions81. This gene is most consistently identified 
mutated gene in PCG cases, however frequencies of specific types or patterns of mutations within 
CYP1B1 vary among ethnic groups81. For example, the current largest study of sequence variants 
in a cohort of nonconsanguineous PCG cases (n=47 cases) from the United States found that 
CYP1B1 was the main causative gene in the US population, but mutations in this gene were less 
common than in Arabic or Romany populations10. The authors claimed that this finding suggested 
that other genes may be accountable for PCG in a US population and that more studies were 
needed10. The sequencing data from this study will be used as the replication set for our findings. 
 Mutations in CYP1B1 have also been discovered to be associated with other phenotypes 




2.3.1.2 Latent transforming growth factor  binding protein 2 (LTBP2) 
  LTBP2 is an extracellular matrix protein that interacts with fibrillin containing 
microfibrils11,86,87. It is expressed in the trabecular meshwork and ciliary zonules in the eyes11,87. 
The LTBP2 gene is located near the GLC3C locus on the q-arm of chromosome 14 (14q24.3)69.  
 In 2009, two papers were published identifying LTBP2 as the disease-causing gene in 
Iranian11, Pakistani and Gypsy families8. The current largest study of sequence variants in a cohort 
of nonconsanguineous PCG cases from the United States included 47 families, but did not identify 
any disease-causing mutations in this gene10. Interestingly, case-control studies of over 300 Han 
Chinese, 46 Turkish and 94 British individuals also showed no deleterious mutations in LTBP2 in 
CYP1B1-negative patients88,89. Currently there are six reported mutations listed as linked to 
primary congenital glaucoma in the Human Gene Mutation Database90.  
2.3.1.3 Myocilin (MYOC) 
 The MYOC gene has previously been associated with juvenile and primary open-angle 
glaucoma91,92.  It codes for a protein which was originally named the trabecular meshwork 
inducible glucocorticoid response protein (TIGR)69, however the name was later changed to 
myocilin (MYOC) by Kubota et al in 199793. Mutations in MYOC have been linked to the reduced 
secretions of myocilin and the formation of insoluble aggregates in cultured trabecular meshwork 
cells94, however the exact causal mechanism behind how these mutations cause glaucoma is yet to 
be elucidated. Disease causing MYOC mutations have been identified in families in both the 
presence and absence of CYP1B1 mutations95. There is also evidence of interactions between 
CYP1B1 and MYOC in primary congenital glaucoma96. A case of PCG was found to be a double 
heterozygote for CYP1B1 and MYOC loci, which suggests a digenic mode of inheritance95, while 




 Mutations in MYOC are more rare than other mutations in primary congenital glaucoma, 
with only three being reported in the Human Gene Mutation Database98. There were no disease-
causing causing mutations within the cohort of 47 primary congenital glaucoma cases in the US10 
and only two in a molecular study of primary congenital glaucoma in South Korea99.  
2.3.1.4 Paired-like homeodomain transcription factor 2 (PITX2) 
 PITX2 encodes a transcription factor important in embryonic development and tissue 
morphogenesis6. Mouse models have shown that PITX2 is required for normal ocular 
development100,101 Additionally, mice that only have one functional copy of PITX2 show the same 
ocular malformations of Axenfeld-Rieger syndrome and associated glaucoma102. Mutations in 
PITX2 have also been associated with Peters anomaly54.  
 PITX2 is also known to interact directly with FOXC1, another transcription factor, and act 
as a negative regulator. This means that mutations in PITX2 could lead to resulting phenotypes, at 
least in part, by affecting function or expression of FOXC1103.  
2.3.1.5 Forkhead box C1 (FOXC1) 
 The forkhead box family of transcription factors are important regulators of 
embryogenesis, cell migration, differentiation, and fate determination104. FOXC1 is expressed in 
the trabecular meshwork during development and remains present in the adult iris105. It is also 
expressed in the heart which is a tissue that is affected in Axenfeld Rieger syndrome106. The 
mechanisms by which FOXC1 mutations cause Axenfeld-Rieger syndrome are yet to be 
elucidated, but may relate to haploinsufficiency which is when an individual only has a one 
functioning copy of a gene which can’t produce enough gene product6. FOXC1 mutations have 




anterior chamber defects, there are reports of multigenerational families in which multiple 
members share a single base pair change but members are diagnosed with Axenfeld Rieger 
syndrome, Peters anomaly, or both48,108.  
 The functional feature of FOXC1 is a conserved 110-amino acid forkhead domain, which 
allows the protein to bind to DNA and mediates protein-protein interactions6. Many of the 
mutations found in Axenfeld-Rieger syndrome cases are located in this region of the gene108,109, 
however some are found in other regions of the gene109.   
2.3.1 Non-genetic exposures 
 Very little is known about non-genetic risk factors for primary congenital glaucoma and 
anterior chamber defects. Many of the studies come out of countries with high rates of 
consanguinity. One case-control study of 52 PCG cases and 38,151 population controls from 
Hungary investigated the association between maternal demographic and socioeconomic status 
(SES) and primary congenital glaucoma110. They found a higher association with disease among 
unmarried (OR=10.1, 95% CI= 5.5-18.6) and unemployed mothers (OR=13.6, 95% CI= 5.7-
32.5)110. Mothers of high employment status showed an inverse association with disease (OR=0.2, 
95% CI= 0.1-0.5) whereas those with a low employment status were more likely to have children 
born with the defect (OR=12.2, 95% CI= 6.1-24.6)110. They also found increased associations 
among certain maternal occupations (agriculture, stay at home with children) and inverse 
associations among others (industry, trade, other). Hungarian gypsies make up the lower SES class 
in this country, possibly explaining the large estimates of association found in this study. The same 
group published a study two years earlier that showed that compared to population controls, PCG 
cases had a shorter gestational age (p=0.0005), were more likely to be a preterm birth (OR=4.0, 




PCG were more likely to be a higher birth order number compared to population controls 
(p=0.03)111. This group did not find any significant associations between acute infectious diseases, 
but did find that mothers of PCG cases were more likely (OR=10.8, 95% CI= 2.6-45.0) to have 
thyroid diseases111. The use of pregnancy supplements was also investigated in this study, however 
limited use by case mothers mean that any interpretations must be made cautiously. Inverse 
associations with PCG were found for mothers who used iron (OR=0.2, 95% CI=0.1-0.4), and 
folic acid (OR=0.3, 95% CI= 0.2-0.6), vitamin D (OR=0.4, 95% CI= 0.2-0.8) supplements111. 
There were also suggestions of inverse associations with calcium, vitamin E, and multivitamin 
supplement use111. The authors concede that many of the findings from this study are consistent 
with the Gypsy demographics of several of the mothers. Although it is not reported how many of 
the 52 cases are of Gypsy descent, the authors believe that at least 28 of them are of Gypsy origin 
and only 6 are confirmed to be non-Gypsy111.  
 A recent analysis of NBDPS data by Forestieri et al112 is one of the first studies to examine 
a wide array of potential risk factors for PCG in a population-based sample. Consistent with 
previous reports, PCG cases were more likely to be male and have lower birth weight compared 
to controls. In this population, smoking and regular alcohol use were found to be inversely 
associated with PCG, differing from the Hungarian study110,111 which had found an increased risk. 
Other findings that differed from previous reports were null findings for opioid use, antibacterial 
medication use during pregnancy, and higher birth order. Novel findings included a higher risk 
among those who used antihypertensive medications or NSAIDs during pregnancy, and Non-




2.4 Maternal diet 
2.4.1 Overview 
 A woman’s diet before and during pregnancy are important because she will be providing 
nutrition for both herself and the developing fetus. It also represents an important modifiable 
behavior which has been shown to have direct and indirect effects on the child. For example, in 
mice, high fat and high sugar diets, characteristics typical of a Western-style diet, have been shown 
to change metabolic patterns in the mother which has consequences for maternal nutrient allocation 
for the fetus113. At the fetal level, maternal nutrition has been shown to have direct effects on gene 
expression114,115, gene methylation116,117, and eye development118.  
2.4.2 Measures of diet 
 Traditionally diet research has focused around the associations between disease and 
specific nutrients, however focusing only on individual nutrients will ignore the complex 
combinations of nutrients that have interactive or synergistic effects within the body. There is also 
a high intercorrelation of some nutrients, and thus lack of ability to untangle independent effects 
when included in the same statistical model, which provides a methodologic limitation of this type 
of single-nutrient analysis119. For those reasons, much of the current literature focuses on more 
holistic approaches to measures of diet.  
 Dietary pattern indexes measure maternal intake compared to some type of scale of diet 
quality. Types of diet quality scores include: the Diet Quality Index for Pregnancy (DQI-P)120, the 
Healthy Eating Index121, the Alternative Health Eating Index122, the Recommended Food Score123, 




receive a score for each component. These component scores are then added together for a total 
score.   
 Another holistic approach to measuring diet is to create dietary patterns through data-
driven approaches. These approaches do not rely on prior criteria which diets are measured against, 
instead they allow the data to determine variables or groups that best represent diets which emerge 
within a study population. These types of models include: factor analysis, principal components 
analysis, mixture modeling, and latent class analysis.  
2.4.3 Maternal Diet and Other Birth Defects 
 There are no published studies on the association between maternal diet and primary 
congenital glaucoma or anterior chamber defects, however there are a number of studies which 
have investigated the association of maternal diet and other birth defects.  
 Within the NBDPS, a higher diet quality has been shown to be associated with a reduced 
risk of anencephaly124, cleft lip124, cleft palate124, and some conotruncal and septal heart defects125. 
A trend toward a reduced risk was also seen with increasing DQI-P scores in both microtia126 and 
spina bifida124. A better diet quality was also found to be associated with a reduced risk of 
gastroschisis among Hispanic women.22    
 Data-driven dietary patterns have also been investigated within the NBDPS. In Sotres-
Alvarez et al. four dietary patterns were discovered and were named: Prudent, Western, Low-
Calorie Western, and Mexican23. Among mothers who did not use vitamin/mineral supplements, 
mothers in the Western, the Low-Calorie Western, and the Mexican dietary pattern classes were 
all significantly more likely to have a child with a neural tube defect compared to mothers in the 
Prudent class23. They were also more likely to have septal and some conotruncal heart defects 




2.5 Section 2 summary 
 Very little is known about non-genetic risk factors for PCG and ACDs. The majority of  
populations that have been used to study these are not generalizable to the United States because 
they are in ethnically homogenous populations where consanguinity is high with potentially 
different exposure patterns9,43,73. Another comprehensive investigation on non-genetic risk factors 
has been done within NBDPS, a population-based case-control study in the United States. Maternal 
diet represents an interesting modifiable risk factor that has yet to be studied in relation to PCG 
and ASDs. This is despite the fact that maternal nutrition has been shown to have direct effects on 
gene expression114,115, gene methylation116,117, and eye development118. At the population level, 
maternal diet quality has been shown to be inversely associated with some birth defects such as 
anencephaly124, cleft lip124, cleft palate124, and some conotruncal and septal heart defects125. 
Additionally, certain diet patterns were found to be associated with increases in neural tube defects, 
septal and some conotruncal heart defects23.   
Overall, the genetics of PCG and ASDs have provided some etiologic clues. However, 
work in more ethnically heterogeneous populations, like those in the United States, have failed to 
find the same disease-causing variants. While mutations in CY1B1 are found in populations from 
the United States, they are found at a much lower frequency than populations of Slovakian Roma 
Gypsies, Pakistani, Indian, and Brazilian descent9,10. These findings have suggested that alternative 
mechanisms or genes underly PCG cases in the United States. Our sequencing aim will focus on 





CHAPTER 3. – STUDY DESIGN AND METHODS 
3.1 Study overview 
 Broadly, this goal of this dissertation is to investigate potential risk factors for primary 
congenital glaucoma and anterior segment defects of the eye using data from the National Birth 
Defects Prevention Study (NBDPS). For Specific Aim 1, maternal nutrition data collected during 
maternal interviews will be used to investigate the relationship between maternal diet and PCG 
and ASDs. In Specific Aim 2, data from whole-exome sequencing will be used to describe the 
genetic landscape of of a subsample of PCG cases in the NBDPS.  
3.2 National Birth Defects Prevention Study 
 This study uses data from the National Birth Defects Prevention Study which is a 
population-based case-control study conducted in 10 states across the United States of America 
(Figure 3.1)127. Infants included in NBDPS had an estimated delivery date between October 1, 
1997 and December 31, 2011. Active population-based surveillance programs were employed in 
each of the participating states to identify cases. Cases were considered eligible if they had one or 
more of the over 30 major birth defects identified by this study, however any infants that were 
recognized or strongly suspected to be related to single-gene defects or chromosomal 
abnormalities were excluded127, which is done because the purpose of NBDPS is to investigate 
unknown causes of birth defects. Cases are made up of livebirths and stillbirths greater than 20 
weeks gestation or at least 500 grams and, where available, elective terminations of prenatally-
diagnosed defects at any gestational age127. Controls are live-births who were selected at random 




TX)127. Controls were not matched to cases; however, they were selected from the same 
geographical region and time periods as cases. Participation rates varied from center to center and 
over time, but overall 67% of cases and 65% of controls who were invited to participate chose 
to.127 Additional details on the study design have been published extensively.127 The response rates 
for PCG and ASDs can be found in Table 3.1.  
 






Table 3.1. Response rates by PCG and ASDs by center and total. 






New Jersey 100% 
New York 78% 





 Upon enrollment, mothers were asked to complete a detailed computer assisted telephone 
interview (CATI). Sections covered in the interview include demographics, pregnancy history, 
maternal conditions and illnesses, family history, lifestyle and behavioral factors, medication use, 
multivitamin use before and during pregnancy, environmental exposures, occupational history, 
physical activity, and maternal nutrition. Biological specimens were also collected in the form of 
buccal cells for DNA extraction and genetic analysis127. In 2017 the CDC led an effort for whole-
exome sequencing of a subset of these samples.  
 Cases were initially clinically diagnosed by a health care provider not affiliated with the 




site. More extensive birth defect classifications were done for cases corresponding to mothers who 
chose to participate in the NBDPS. Cases were classified as: isolated, multiple, or complex. If  the 
child had a single major defect with or without any number of minor defects which weren’t 
recognized as a syndrome, they were considered an isolated case127. When more than one major 
defect was found that were not known to be related, subjects were considered to have multiple 
defects127. Complex cases were defined as “a pattern of major defects that are embryologically 
related and likely represent an early problem in morphogenesis,  often akin to a developmental 
field defect”127. More detailed guidelines can be found in Rasmussen et al.129  
 The NBDPS study was approved by the institutional review boards of the University of 
North Carolina at Chapel Hill, the Centers for Disease Control and Prevention, and the 
collaborating study centers.  
3.3 Methodology for Specific Aim 1 
3.3.1 Study population 
 For this aim, the study population includes all cases of primary congenital glaucoma and 
anterior segment defects enrolled in the NBDPS between January 1, 2000, to December 31, 2011. 
Mothers with a reported total energy intake of < 500 kcals or >5000 kcals were excluded. In 
addition, plural births, those resulting from donor egg or sperm, those with a gestational age of < 
15 weeks, or those cases with co-occurring anopthalmia or micropthalmia were excluded.  
3.3.2 Exposure assessment 
3.3.2.1 Exposure assessment overview 
 Maternal interviews were conducted via telephone using a standardized computer-based 




environmental, behavioral, and dietary data. Dietary data was measured through the use of a 
shortened Willet food frequency questionnaire (FFQ)23. Interviews were administered between 6 
weeks past the estimated date of delivery of the infant and no later than 2 years after this date.  
 The primary exposure of interest in Specific Aim 1 is maternal diet. It will be evaluated in 
the following three ways using data collected as a part of the FFQ.  
3.3.2.2 Individual micronutrients 
 The intakes of individual micronutrients were calculated based on answers to the FFQ. 
Mothers were asked how frequently they consumed each of the 58 foods during the year prior to 
pregnancy. In total, there were 16 possible response categories for frequency ranging from never 
or less than once a month to 6 or more times per day. Intakes in grams per day were then calculated 
by multiplying the consumption frequency to a standard portion size which was listed on the 
questionnaire for each of the items. The estimates of each nutrient were determined based on the 
US Department of Agriculture National Nutrient Database, version 20130. Results will be stratified 
by periconceptional vitamin supplementation.    
3.3.2.3 Diet Quality Index for Pregnancy (DQI-P) 
 There are limited valid biochemical indices to measure whether an individual is getting 
enough of certain nutrients in their diet. One such measure is the use of hemoglobin concentration 
as a marker for iron status. When these indices are available, they lack the ability to assess more 
than one nutrient at a time. Composite score measures of diet quality are able to capture the 
complexity of diet by combining intakes of food and nutrient components reported in dietary 
assessment tools like food frequency questionnaires and comparing each participant’s diet to 




of the most common diet quality composite scores are Diet Quality Index and the Healthy Eating 
Index, however neither of these measures incorporate the changes in dietary recommendations 
when a woman is pregnant. In 2002 Bodnar and Siega-Riz adapted the Diet Quality Index to 
incorporate these changes and developed the Diet Quality Index for Pregnancy (DQI-P)120. 
Adaptations include dropping the meal pattern component but adding a sweets component. In 
addition, it scores each component based on quartiles rather than absolute values. The DQI-P is 
based on 8 dietary components which include grains, vegetables, fruits, folate, iron, calcium, 
percentage of calories from fat120. Each component has a maximum of 10 possible points and is 
weighted equally. 
 Since it was developed, the DQI-P has been used in multiple racial and ethnic populations 
including African Americans120, Caucasians120,131, and Native Americans131. One study showed 
that among low-income pregnant women, Native Americans had significantly lower DQI-P scores 
compared to Caucasians (51.8 vs. 54.2), but overall all women in the population were not meeting 
dietary recommendations131. Others have shown that individuals who live more than 4 miles from 
a supermarket132 and those who are classified as obese had an increased odds (OR=2.16, 95% CI= 
1.2-4.0; OR=1.87, 95% CI= 1.37-2.55, respectively) of being in the lowest compared to the highest 
tertile of DQI-P score133. As mentioned before, the DQI-P has been used in the NBDPS where it 
was seen that higher DQI-P scores were associated with lower risk of neural tube defects and 
orofacial clefts124, as well as gastroschisis among Hispanics22.         
 In this study, we will include the adapatation of the DQI-P that has been used in recent 
NBDPS studies by Carmichael et al124 and Feldkamp et al22.  
 The component scores that make up the DQI-P are each calculated individually. For the 




values using the United States Department of Agriculture (USDA) nutrient database (version 19) 
for all nutrients except choline, for which the USDA version 20 was used because it was considered 
more complete134,135. For the grains, vegetables, and fruits components, food items were mapped 
from the FFQ items to the specific food groups in the DQI-P as outlined in Carmichael et al124. To 
calculate servings per day for grains, vegetables, and fruits, the following formula was used: 
 
 (servings/day  x  grams/serving for each food item in the group) 
(mean grams/serving of all foods in the component) 
 
To calculate servings per day for sweets, the following formula was used: 
 
    (servings/day  x  grams/serving for each non-soda sweet food item)    
(mean grams/serving of all foods in the component) + servings/day of soda 
 
To account for variability in proportion sizes of different food items within each component, the 
equations above divided the sums of grams per day by the mean grams per serving sizes of all 
foods within that component. 
 For grains, vegetables, fruits, folate, iron, and calcium, participants in the lowest decile of 
received a score of 0, those in the second lowest decile received a 1, up to participants in the highest 
decile who received a score of 9. Sugar intake will be scored in the opposite manner where 
individuals in the lowest decile will be given scores of 9 and those in the highest decile will be 
given a score of 0. Percentage of calories from fat has four categories:  30%, >30% to  35%, 




DQI-P scores will then be calculated by summing the component scores. Mothers will then be 
divided into quartiles and compared to reference, or the lowest quartile of DQI-P scores. 
3.3.2.4 Latent Class Analysis (LCA) 
 Identifying dietary patterns offers additional advantages over individual nutrients and diet 
quality scores. These patterns allow for interactions between single nutrients while not measuring 
against prevailing hypotheses or guidance from current dietary recommendations.  
 Data-driven approaches that have been used to derive dietary patterns include principal 
components analysis (PCA)136, exploratory factor analysis (EFA)137, and cluster analysis138. These 
methods are considered data reduction methods and do not consider dietary patterns as unobserved 
random variables (latent variables)139. In PCA and EFA, food items are grouped together according 
to their correlations to each other and individuals have a score for each dietary pattern. Latent 
variable models offer many advantages when used in dietary pattern analyses including the ability 
to account for correlated errors, the ability to adjust for covariates, and multi-group analyses140.  
 Latent class analysis (LCA)141, a type of latent variable model, was used in this study. 
Broadly, in LCA individuals are assumed to belong to one of a set number of mutually exclusive 
classes for which membership is unknown. The latent model is built from a multinomial logistic 
model and takes into account associations between input variables and determines latent classes, 
or groups, which can explain these associations. In our study, the latent classes are the dietary 
patterns and the input variables are intake of nutrients reported by the mothers in the FFQ. Each 
participant is then given a predicted probability of belonging to each group based on levels of their 
input variables. This method then allows for an estimation of the risk of an outcome for each group 




 In this study, we used the same approach as Sotres-Alvarez et al23 where dietary patterns 
were derived from 64 food items relative to total consumption and adjusted for energy intake from 
control data only. Relative consumption was categorized into four levels: no consumption and 
tertiles of nonzero consumption. For foods there were consumed by less than 20% of the women, 
binary variables will be created: consumed or not consumed. Ubiquitously consumed foods did 
not have a nonconsumption category and instead have quartiles of nonzero consumption. Dietary 
classes were interpreted and named based on conditional food intake probabilities. We began by 
specifying four classes (dietary patterns) to look for similarities with previous literature in the 
NBDPS, but determined that this was the best choice based on the Bayesian information criteria 
(BIC). 
 Two sets of parameters were estimated: regression coefficients predicting class 
membership and conditional probabilities of the observed indicators given the class. These two 
sets of probabilities were then used via Bayes’ theorem to predict each mother’s probability of 
belonging to each class. Mothers were then classified for the class for which they have the highest 
probability of belonging to.  
3.3.3 Covariate selection 
 We used findings from Foresteiri et al, along with an extensive literature review on 
maternal nutrition and congenital birth defects22,23,124,125  to develop a directed acyclic graph 
(DAG; Figure 3.2). In this analysis, Table 3.1 outlines the variables and coding schemes for the 
adjustment set that will be used for this analysis. The variable categories were chosen based on 











Table 3.2. Variables and planned initial coding schemes for confounders in Aim 1. 
Variable Coding Scheme Variable Range 
Maternal Age Continuous 14 - 49 












Total kcal Intake Continuous 503 - 4986 










* beginning three months prior to conception through three months after conception 
3.3.4 Modeling strategy 
3.3.4.1 Individual nutrients 
 Functional form analyses will be done to evaluate continuous, quadratic, spline, and 
categorical forms of each of the 16 micronutrients listed in Table 3.4. Simple logistic regression 
will be used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). We will calculate 
ORs and 95% CIs for each micronutrient in two models: 1) adjusting for total energy intake only, 






Table 3.3. List of micronutrients evaluated for associations with PCG and ASDs. 
Betaine (mg) Magnesium (mg) 
Calcium (mg) Retinol (µg) 
Alpha Carotene (µg) Riboflavin (mg) 
Beta Carotene (µg) Vitamin A, RAE (µg) 
Choline, total Vitamin B12 (µg) 
Copper (mg)  Vitamin B6 (µg) 
Folate, DFE (µg) Vitamin E (mg) 
Iron (mg) Zinc (mg) 
3.3.4.2 DQI-P 
 A DQI-P score will be calculated for each mother based on the sum of their individual 
component scores as described above. The distribution of the DQI-P score among controls will be 
used to determine quartiles. We plan to calculate ORs and 95% CIs using simple logistic regression 
for each of the quartiles using the lowest quartile as the reference.  
3.3.4.3 LCA 
 Each mother will be assigned to a dietary pattern for which they have the highest 
probability of belonging to. This nominal predictor will be as the exposure variable in a simple 
logistic regression model.  
3.3.5 Power Calculations 
 Minimal detectable odds ratios (ORs) were calculated for all primary congenital glaucoma and 
related anterior chamber defects together (~175 cases) and separately for primary congenital 




interviewed cases, and instead take into account that some cases may need to be excluded due to 
incomplete data on demographic information. All calculations were performed in EpiSheet 
(Rothman © 2002, 2015) assuming two-tailed alpha-level of 0.05 and 80% power.  
 We plan to divide our data into quartiles of each individual nutrient mentioned above 
according to the distribution in the control pattern. We also plan to use this approach for the DQI 
as was done in previous NBDPS studies22,124.  In the most conservative of the planned analyses, 
we will have approximately 107 cases of primary congenital glaucoma without anterior chamber 
defects. With this analysis plan, we should have adequate power (=80%) to detect ORs of 
approximately 0.5 or 1.80 when exposure frequencies are 25% (quartiles) among mothers in the 
control group. For the dietary patterns analysis, the prevalence of the patterns has been estimated 
within the NBDPS control population in a previous study. There were four dietary patterns 
identified using latent class analysis including the Prudent, the Western, the Low-Calorie Western, 
and the Mexican dietary patterns which ranged from 15% (Mexican) to 32% (Prudent Based on 
the prevalences of dietary patterns and this conservative case number, we would have power 
(=80%) to detect minimum ORs of 1.75-1.9623.      
3.4 Methodology for Specific Aim 2 
3.4.1 Study population 
The study population for Specific Aim 2 will include complete family trios (mother/father/baby) 
from the NBDPS from whom buccal (cheek) samples were collected and children were diagnosed 
with PCG. For this dissertation, we will not look at whole-exome sequencing of ASD trios due to 
differences in inheritance patterns. Any PCG cases that were conceived using donor egg, sperm, 
or embryo were excluded and all family members had to have at least 200 ng of DNA available to 




3.4.2 Exposure Assessment 
3.4.2.1 Buccal cell collection & DNA isolation 
 One of the aims of the NBDPS was to “better understand the role that genetic and 
epigenetic factors play in the etiology of birth defects”127. After completion of the interview, 
families were mailed a buccal cell collection kit which included documents for informed consent, 
6 cytobrushes (2 per family member), instructions for use, and a postage-paid return mailer. In 
2002, two study centers with low participation rate began adding a $20 incentive for completion 
of the buccal cell collection kits. By 2008 this was implemented in all centers127. Collection kits 
were modified in mid-2003 to replace the cytobrush packaging after concerns about DNA 
degradation during transit127.  
 Prior to 2003, DNA was extracted at each center using different methods127, however after 
2003 a centralized laboratory was established to improve consistency and standardize extraction 
and quality control methods. For each participant, one cytobrush remained at the local center142. 
At the centralized laboratory DNA was extracted from one of the cytobrushes using either a 
phenol-chloroform method or Gentra Purgene (Qiagen). Amounts of DNA isolated was 
assessed by quantitative real-time PCR using the human RNaseP gene and STR markers were used 
to assess DNA quality. Quality control standards included 0.1 ng/uL DNA, successful PCR 
amplification after at least two attempts with at least one STR marker, and alleles consistent with 
the reported family relationship127.   
3.4.2.2 Whole-exome sequencing and alignment 
 Specimens from case trios that had at least 200 ng of genomic DNA were sent to Dr. Larry 




were measured by Qubit and DNA quality was checked by running a small portion on an agarose 
gel. Samples were prepared for sequencing at the NIH Intramural Sequencing Center (NISC) using 
100 ng of genomic DNA and the Accel-NGS 2S Plus DNA Library Kit. Additional modifications 
included modified PCR cycling conditions to improve recovery of high GC regions and swapping 
a polymerase at the post-capture library amplification step.   
 The Nimblegen SeqCap EZ Exome + UTR Library (Version 3.0) was used for whole-
exome sequencing. Briefly, this kit shears DNA, targeted fragments are captured by probe 
hybridization, which are then amplified. Samples were then pooled and sequenced on an Illumina 
HiSeq 2500 instrument.  Image analysis and base calling was performed using Illumina Genome 
Analyzer Pipeline software (version 1.18.64.0) with default parameters 
 Sequence reads were aligned to the human reference sequence (NCBI build 37/hg19) using 
the Illumina aligner “ELAND” (Efficient Large-scale Alignment of Nucleotide Databases). When 
at least one read in a pair maps to a unique location in the genome, that read and its pair are then 
subjected to a more accurate alignment with Novoalign v3.02.07.  The aligned lane bam files are 
merged, sorted, and indexed. Sequenced bases with a probability of an incorrect base call of 1 in 
100143, or a phred quality scores less of than 20, where ignored. 
3.4.2.3 Identification of Candidate Variants by the University of Washington Center for 
Mendelian Genomics  
 Our collaborators at the University of Washington Center for Mendelian Genomics (UW-
CMG) reviewed the whole-exome sequencing data and pedigree files. Using these two files, they 
confirmed the sex of all participants and the relationships reported within triads. All of the triads 
in this study population included affected children and non-affected parents. Using this 




recessive, and X-linked de novo models of inheritance to generate a list of candidate genes and 
variants which will meet the filters outlined in Table 3.5. 
 
Table 3.4 Filters used in determination of candidate variants using different models of inheritance. 
Filter Level Requirement 
Genotype  Read depth  4 
 Genotype quality  20 
Variant   Frequency  0.05 in UW-CMG subjects 
 MAF < 0.05 in NHLBI GO Exome Sequency 
Project        (ESP6500) and/or 1,000 Genomes 
 Not annotated in SeattleSeq137 as: 
              - Intergenic 
              - Intron 
              - Synonymous or Synonymous-coding 
              - Untranslated region (utr) 
              - 3’ Untranslated region (utr-3) 
              - 5’ Untranslated region (utr-5) 
              - Near gene- 3’ end 
              - Near gene- 5’ end 
              - No coding 
Person  All members in each family must have the correct 
genotype given the inheritance model 
 
After these analyses are complete, the UW-CMG group provided us with a written report outlining 
the list of candidate variants within each family. Specific attention was paid to genes which are 
known to underly other Mendelian conditions, including some which have phenotypic overlap. In 
addition, we provided a comprehensive list of genes important in fetal eye development and/or 
those that are in a signaling pathway that interacts with genes known to be causal in PCG (CYP1B1, 




3.4.3 Initial analysis plans for Aim 2  
 Initial plans for Aim 2 included three sub-aims. In sub-aim 1 we had intended to focus on 
calculating risk using a log-linear model, in common SNPs present in genes which have previously 
been identified as causal for PCG and ACDs in the literature. Sub-aim 2 was to focus on less 
common SNPs and single nucleotide variants (SNVs) in genes outlined in sub-aim 1, but also in 
de novo mutations identified in at least three families in the UW-CMG analysis. Sub-aim 3 was to 
investigate gene-environment interactions.  
 Upon receiving the UW-CMG report, we discovered that the only gene with variants in more 
than one family was CYP1B1, though there were multiple genes with biologic plausibility found 
in individual families. Thus, we decided that the efficient and effective focus of Aim 2 would be a 
descriptive analysis of the findings, with a special emphasis on genes which hadn’t previously 
been described in PCG patients.  
3.4.4 Updated analysis for Aim 2 
 The goal for Aim 2 is to evaluate the prevalence of variants in genes which have previously 
been linked to PCG such as CYP1B1, LTBP2, MYOC, and FOXC1. We will investigate whether 
any variants are novel, compare the prevalence of variants in each gene to previous literature, and 
evaluate if there appears to be segregation of variants by maternal race/ethnicity.  
 Further, we plan to utilize the strengths of whole-exome sequencing to identify rare, 
pathogenic variants in genes which previously have not been investigated for PCG. Efforts will be 
focused on genes which are known to underly other Mendelian conditions, especially those with 
phenotypic overlap, and genes which were identified in eye development signaling pathways or 
are known to interact with genes previously linked to PCG. The role of each gene and 




mammalian eye. A literature review will be done on each variant to determine whether it has 





CHAPTER 4. – MATERNAL DIET AS A RISK FACTOR FOR PRIMARY 
CONGENITAL GLAUCOMA AND DEFECTS OF THE ANTERIOR SEGMENT OF 
THE EYE 
4.1 Introduction 
Childhood glaucoma encompasses cases of primary congenital glaucoma (PCG) and 
glaucoma with non-acquired ocular anomalies144. These conditions are rare, with prevalence 
ranging from 1 in 10,000 (PCG) to 1 in 100,000 (Peters anomaly45) live births. Two diagnostic 
differences between these groups is if glaucoma co-occurs with ocular defects and the timing of 
glaucoma presentation. PCG typically presents in the absence of co-occurring ocular anomalies. 
Approximately 25% of cases are diagnosed at birth and close to 80% are diagnosed within the first 
year of life1. Glaucoma with non-acquired ocular anomalies includes a collection of conditions 
where glaucoma presents secondary to anterior segment dysgenesis (ASDs), which are defects in 
the front portion of the eye present at birth. This group of heterogeneous disorders includes 
conditions such as Axenfeld-Rieger anomaly, Peters anomaly, and aniridia, among others144. Both 
PCG and ASDs result in a restriction of the flow of the aqueous humor, the clear fluid which 
supplies nutrients and removes metabolic waste from the eye, leading to an increased intraocular 
pressure. This can cause blindness if left untreated or if poorly controlled 2. At the genetic level, 
there is some evidence of a shared etiology for PCG and ASDs. Mutations in some of the same 
genes, including CYP1B1 and FOXC1, have been shown to cause both PCG and ASDs107,108.  
Much of the research on PCG and ASDs has focused on the genetics of these conditions 
and little is known about non-genetic risk factors. Many of the findings for non-genetic risk factors 




Hungary, increased risks of PCG were seen among infants of lower birth weight, higher birth order, 
mothers who used tobacco or alcohol during pregnancy, unmarried mothers, and unemployed 
mothers 110,111. In a recent analysis of US-based data from the National Birth Defects Prevention 
Study our research group also found a higher risk of PCG among lower birth weight infants and 
reported a number of new findings such as an increased odds among Non-Hispanic Blacks, 
increased odds with certain medications, and inverse associations with maternal smoking and 
alcohol intake112.  
There are many studies showing an association between maternal periconceptional diet and 
birth defects. Among these are studies of defects in tissues that arise from the neural crest cells, 
the same cells that differentiate into the trabecular meshwork. For example, epidemiologic studies 
have shown that diet quality124 and certain dietary patterns23,145 are associated with neural tube 
defects (NTDs). While there are no studies on the role of maternal diet and congenital glaucoma, 
there have been studies linking maternal deficiencies of folic acid15,17, zinc19 and vitamin C20 to 
other structural malformations of the eye. In addition, animal studies have shown structural 
abnormalities in the trabecular meshwork could be prevented by molecules that act as free radical 
scavengers or have anti-oxidant capacities21. Apart from one study which reported total folate 
intake, the current literature on maternal nutrition and congenital glaucoma  is limited to prenatal 
folic acid and/or vitamin use and findings are equivocal 111,112. Vogt et al111 found inverse 
associations for all vitamin/mineral supplements investigated; some were statistically significant 
(iron, folic acid, and vitamin D) and others were only suggestive with large confidence intervals 
(calcium, vitamin E, and multivitamins). Conversely, Forestieri et al112 found the suggestion of an 
increased odds among those mothers who used folic acid supplements during early pregnancy. 




inverse associations were seen for middle quartiles and no association was seen in the highest 
quartile. In this study, we expanded on these findings by comprehensively evaluating maternal diet 
as a risk factor for PCG and ASDs.  
4.2 Materials and Methods 
Study Population 
Data for this analysis come from the National Birth Defects Prevention Study (NBDPS), a 
large population-based multicenter case-control study of over 30 major birth defects in the United 
States. Detailed methods have been reported previously 127. Briefly, case infants were identified 
through birth defects surveillance systems in ten states (AR, CA, GA, IA, MA, NJ, NY, NC, TX, 
and UT) and controls were live-born infants without major birth defects who were selected at 
random from vital records (IA, MA, NC, NJ, UT, CDC-MACDP) or hospital birth records (AR, 
CA, NY, TX).  Controls were not matched to cases; however, they were selected from the same 
geographical region and time periods as cases. The NBDPS was approved by the Institutional 
Review Board (IRB) at the Centers for Disease Control and Prevention, and each study center also 
received local IRB approval.  
Case Classification 
Clinical geneticists at each study center reviewed abstracted medical records to confirm 
that identified cases met eligibility criteria, which included diagnosis by an ophthalmologist within 
the first 12 months of life. Cases with defects of known etiology, including single-gene disorders 
and chromosomal abnormalities were excluded. Cases of PCG and ASDs (Peters anomaly, 
Axenfeld-Rieger anomaly, aniridia, lens coloboma, and aphakia/spherophakia) were eligible for 
NBDPS from birth years 2000-2011. We included both isolated and non-isolated PCG and ASD 




of demographic and clinical risk factors are quite similar between cases with isolated vs. non-
isolated defects.    
Risk Factor Ascertainment 
Upon enrollment in NBDPS, mothers were asked to complete a standardized computer 
assisted telephone interview (CATI) between 6 weeks to 24 months after the infant’s estimated 
date of delivery. Interviews included a range of demographic, clinical, lifestyle, and behavioral 
factors. Participation rates varied from center to center and over time, but overall 67% of cases 
and 65% of controls who were invited chose to participate.  On average case mothers were 
interviewed approximately 5 months later than control mothers (12.5 months vs. 7.5 months after 
the infant’s date of birth). Part of the interview included a 58-question version of the validated 
Willet food frequency questionnaire146 (FFQ) modified for NBDPS, which was used to assess 
dietary intake for the year before pregnancy.  Mothers were asked to report their average frequency 
of consumption based on the serving size for each food item. These values were used to estimate 
the average daily intake, with nutrient calculations being derived from the U.S. Department of 
Agriculture, version 25 nutrient database134.  
Mothers were also asked about vitamin and mineral supplement use from 3 months before 
they became pregnant until the end of their pregnancy. Frequency of use and start- and stop-dates 
were recorded. If a mother did not remember specific dates, she was asked for the approximate 
duration of use. Each product was reviewed to determine whether it contained folic acid and if so, 
it was included in the category of vitamin use. In this analysis, we restricted use to the 
periconceptional period, which includes the 2 months before conception to 2 months after 





Assessment of Pre-Pregnancy Dietary Quality and Dietary Patterns 
The Diet Quality for Pregnancy Index (DQI-P) scores were calculated similarly to 
Carmichael et al124. This score combines six positively scored components (grains, folate, fruits, 
vegetables, iron, and calcium) and two negatively scored components (percentage of calories from 
sweets and fats)120,147. Since the original DQI-P was developed, minor changes have been made 
over time such as the inclusion of sweets, the exclusion of meal patterns, and the use of quartiles 
among controls to rank each component and then sum instead of using absolute values 124,148.  
Latent class analysis (LCA) was used to derive dietary patterns based on participant’s 
consumption of food items from the FFQ after adjusting for caloric intake. LCA is a statistical 
method for identifying subgroups, or “classes”, that are not directly observed within a sample or 
population. This method has previously been described in an analysis of NBDPS data by Sotres-
Alvarez et al23. Briefly, dietary patterns, adjusting for energy intake, were derived using dietary 
intake data among controls. Regression coefficients that predicted class membership and 
conditional probabilities of the observed indicators given the class were used to predict posterior 
probabilities of class membership for both cases and controls. Each subject was then assigned to 
the class for which they had the highest probability of belonging. Despite including slightly 
different birth years for the control group (1997-2005 in Sotres-Alvarez et al vs. 2000-2011 in the 
current analysis), the four dietary classes we saw had similar characteristics to previous work 
within NBDPS. Women in the Prudent class were more likely to consume fruits, vegetables and 
whole wheat breads. Those in the Mexican dietary pattern were more likely to consume tortillas, 
refried beans, avocados, and similar to the Prudent dietary pattern, fruits and vegetables. Finally, 
high intake of regular sodas, French fries, and white bread consumption characterized those in the 




terms of calorie intake (those in the Low-Calorie Western consumed 222 fewer calories) and 
patterns of probabilities of consumption (those in the Low-Calorie Western dietary pattern had 
higher extreme probabilities, such as higher levels of no consumption). 
Statistical Analysis 
We excluded non-singleton births (6 cases; 275 controls), pregnancies conceived with use 
of donor egg or sperm (1 case; 28 controls), mothers with energy intake <500 or > 5,000 kcal (4 
cases; 154 controls), and mothers with more than one food item missing from the FFQ (9 cases; 
448 controls). Finally, cases with co-occurring anophthalmia or microphthalmia were also 
excluded to minimize heterogeneity within the outcome group (15 cases; 0 controls).  
We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals 
(CIs) for individual micronutrients, DQI-P scores, and dietary patterns. Nutrient intakes and DQI-
P scores were divided into quartiles based on the distribution among controls. All analyses were 
adjusted for total energy intake (Kcal). Additional analyses estimated adjusted odds ratios (aORs) 
and were further adjusted for covariates identified by a Directed Acyclic Graph, including maternal 
age (continuous, years), maternal race/ethnicity (non-Hispanic White, non-Hispanic Black, 
Hispanic, Other), periconceptional vitamin supplementation (yes, no), maternal BMI (<18.5, 18.5-
<25, 25-<30, ≥30), and study center. A sensitivity analysis was done stratifying by 
periconceptional vitamin supplementation, based on the a priori assumption that risks may be 
different in women reporting vitamin use149.  
All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). 
4.3 Results 
There were 152 cases (91 PCG and 61 ASD; all livebirths) and 9,178 controls eligible for 




infants, cases were more likely to be low birth weight. The majority of case infants with PCG 
(86%) and ASDs (84%) did not have another birth defect (i.e., the PCG or ASD was considered 
isolated). The majority of mothers self-identified as Non-Hispanic White (59%), but 
proportionally Non-Hispanic Black ethnicity was more common among PCG cases compared to 
control mothers. Compared to control mothers, case mothers were also less likely to report 
smoking during pregnancy, have a slightly higher BMI, and a higher age among ASD cases only. 
Periconceptional vitamin use was high in the study sample with no apparent differences between 
cases and controls (p=0.87). Control mothers had slightly higher daily energy intake (1604.5 kcal) 
compared to mothers of cases with PCG (1550.5 kcal) and ASD (1490 kcal) though they were not 
statistically different (p=0.46 and p=0.20; respectively).  
Associations with various micronutrients and diet quality are shown in Table 4.2. Most 
were consistent with a null finding and were not monotonic across quartiles. However, some of 
the aORs suggested inverse, although imprecise, associations with increasing micronutrient intake. 
Compared to the lowest quartile of intake, all three remaining quartiles of calcium, choline, and 
Vitamin E were associated with consistently lower odds of PCG or ASDs. For example, the aORs 
for PCG or ASDs were lower for those in the highest quartile of choline intake (aOR 0.79, 95% 
CI 0.40-1.55) compared to those in the lowest quartile. Intake of copper and folate showed lower 
odds ratios among those in the middle quartiles, but increased aORs among those in the highest 
quartile. Both zinc and Vitamin A were suggestive of this U-shaped pattern, though ORs in the 
highest quartile of intake were close to, but below, the null value. There did not appear to be any 
association between DQI-P and PCG or ASDs (Q3 aOR 1.03, 95% CI 0.61-1.72; Q4 aOR 0.91, 
95% CI 0.49-1.66 vs. the lowest quartile). Findings were similar with stratification by 




Mothers who belonged to the Prudent and Mexican dietary patterns had lower odds (aOR 
0.82, 95% CI 0.52-1.29, aOR 0.80, 95% CI 0.36-1.78) of having a child with PCG or ASD 
compared to mothers in the Western dietary pattern, but again, confidence intervals included 1.0 
(Table 4.3). Mothers in the Low Calorie Western dietary pattern had similar odds compared to 





Table 4.1. Demographic and clinical characteristics of primary congenital glaucoma and anterior 







 (n= 9178) 
 
 










n (%) or mean (SD) 
Infant Sex    
Female  4445 (48.5) 41 (45.1) 28 (45.9) 
Male 4723 (51.5) 50 (55.0) 33 (54.1) 
Missing 10 0 0 
Gestational Age    
< 37 weeks 751 (8.2) 10 (11.0) 7 (11.5) 
37- 41 weeks 8312 (90.6) 79 (86.8) 54 (88.5) 
≥ 42 weeks 115 (1.3) 2 (2.2) 0 (0) 
Birth Weighta    
<2500 grams 152 (1.8) 5 (6.7) 3 (5.7) 
≥2500 grams 8158 (98.2) 70 (93.3) 50 (94.3) 
Missing 117 6 1 
Maternal 
Race/Ethnicity 
   
Non-Hispanic White 5282 (57.6) 46 (50.6) 37 (60.7) 
Non-Hispanic Black 975 (10.6) 23 (25.3) 8 (13.1) 
Hispanic 2279 (24.8) 16 (17.6) 12 (19.7) 
Other 642 (7.0) 6 (6.6) 4 (6.6) 
Gravidity    
Primigravid 2714 (29.6) 28 (30.8) 18 (29.5) 
Multigravid 6462 (70.4) 63 (69.2) 43 (70.5) 
Missing 2 0 0 
Maternal age at 
delivery 
   
≤ 24 2998 (32.7) 35 (38.5) 19 (31.2) 
25-34 4922 (53.6) 49 (53.9) 28 (45.9) 
≥ 35 1258 (13.7) 7 (7.7) 14 (23.0) 
Paternal age at 
delivery 
   
≤ 24 1956 (21.9) 22 (25.9) 12 (19.7) 
25-34 4792 (53.7) 41 (48.2) 28 (45.9) 
≥ 35 2179 (24.4) 22 (25.9) 21 (34.4) 
Missing 251 6 0 
Maternal smoking    
No 7518 (82.4) 84 (93.3) 52 (85.3) 
Yes 1608 (17.6) 6 (6.7) 9 (14.8) 






   
<18.5 465 (5.3) 1 (1.2) 2 (3.5) 
18.5 - <25 4621 (52.5) 48 (55.8) 31 (54.4) 
25 - <30 2054 (23.4) 18 (20.9) 12 (21.1) 
≥ 30 1656 (18.8) 19 (22.1) 12 (21.1) 
Missing 382 5 4 
Perinconceptional 
Vitamin Use 
   
No 2011 (22.1) 18 (20.0) 13 (21.3) 
Yes 7073 (77.9) 72 (80.0) 48 (78.7) 
Missing 94 1 0 
Daily Energy 
Intake (kcal) 
1604.5 (688.5) 1550.5 (703.0) 1490.1 (669.9) 






Table 4.2. ORs and 95% CIs for individual nutrients for combined primary congenital glaucoma 






ORa 95% CI aORb 95% CI 
Calcium (mg)       
Q1 49 (32.2) 2295 (25.0) 1  1  
Q2 39 (35.7) 2294 (25.0) 0.80 0.52, 1.23 0.79 0.50, 1.25 
Q3 35 (23.0) 2295 (25.0) 0.72 0.45, 1.15 0.73 0.44, 1.20 
Q4 29 (19.1) 2294 (25.0) 0.60 0.34, 1.06 0.63 0.34, 1.16 
Betaine (mg)       
Q1 36 (23.7) 2295 (25.0) 1  1  
Q2 40 (26.3) 2295 (25.0) 1.18 0.75, 1.87 1.14 0.71, 1.85 
Q3 32 (21.1) 2293 (25.0) 1.01 0.62, 1.66 1.01 0.60, 1.70 
Q4 44 (29.0) 2295 (25.0) 1.56 0.95, 2.57 1.52 0.88, 2.60 
Choline, total       
Q1 49 (32.2) 2295 (25.0) 1  1  
Q2 37 (24.3) 2294 (25.0) 0.78 0.50, 1.21 0.84 0.53, 1.33 
Q3 32 (21.1) 2295 (25.0) 0.68 0.41, 1.13 0.70 0.41, 1.18 
Q4 34 (22.4) 2294 (25.0) 0.77 0.40, 1.45 0.79 0.40, 1.55 
Copper (mg)       
Q1 46 (30.3) 2253 (24.6) 1  1  
Q2 42 (27.6) 2333 (25.4) 0.93 0.60, 1.44 0.93 0.59, 1.47 
Q3 26 (17.1) 2297 (25.0) 0.61 0.36, 1.05 0.65 0.37, 1.15 
Q4 38 (25.0) 2295 (25.0) 0.98 0.52, 1.83 1.08 0.54, 2.17 
Iron (mg)       
Q1 43 (28.3) 2294 (25.0) 1  1  
Q2 44 (29.0) 2295 (25.0) 1.10 0.71, 1.70 1.12 0.72, 1.75 
Q3 26 (17.1) 2291 (25.0) 0.68 0.40, 1.14 0.62 0.36, 1.07 
Q4 39 (25.7) 2298 (25.0) 1.13 0.65, 1.97 1.18 0.67, 2.09 
Magnesium 
(mg) 
      
Q1 51 (33.6) 2295 (25.0) 1  1  
Q2 37 (24.3) 2294 (25.0) 0.75 0.48, 1.16 0.74 0.47, 1.18 
Q3 28 (18.4) 2295 (25.0) 0.58 0.34, 0.97 0.59 0.34, 1.04 
Q4 36 (23.7) 2294 (25.0) 0.79 0.41, 1.51 0.90 0.44, 1.85 
Riboflavin 
(mg) 
      
Q1 46 (30.3) 2292 (25.0) 1  1  
Q2 39 (25.7) 2291 (25.0) 0.88 0.57, 1.37 0.91 0.58, 1.43 
Q3 32 (21.1) 2287 (24.9) 0.75 0.46, 1.24 0.73 0.43, 1.22 
Q4 35 (23.0) 2308 (25.2) 0.88 0.49, 1.60 0.87 0.46, 1.63 
Vitamin B6 
(mg) 
      
Q1 48 (31.6) 2310 (25.2) 1  1  




Q3 33 (21.7) 2281 (24.9) 0.77 0.47, 1.26 0.80 0.48, 1.33 
Q4 36 (23.7) 2297 (25.0) 0.91 0.50, 1.68 0.91 0.49, 1.72 
Vitamin B12 
(µg) 
      
Q1 39 (25.7) 2303 (25.1) 1  1  
Q2 45 (29.6) 2289 (24.9) 1.25 0.80, 1.94 1.25 0.79, 1.96 
Q3 27 (17.8) 2297 (25.0) 0.80 0.47, 1.34 0.77 0.45, 1.32 
Q4 41 (27.0) 2289 (24.9) 1.37 0.80, 2.34 1.30 0.75, 2.28 
Vitamin E 
(mg) 
      
Q1 50 (32.9) 2290 (25.0) 1  1  
Q2 39 (25.7) 2300 (25.1) 0.79 0.51, 1.21 0.82 0.52, 1.28 
Q3 30 (19.7) 2297 (25.0) 0.61 0.37, 1.00 0.59 0.35, 1.00 
Q4 33 (21.7) 2291 (25.0) 0.69 0.39, 1.23 0.76 0.41, 1.39 
Zinc (mg)       
Q1 51 (33.6) 2297 (25.0) 1  1  
Q2 31 (20.4) 2293 (25.0) 0.65 0.41, 1.03 0.70 0.43, 1.12 
Q3 31 (20.4) 2290 (25.0) 0.69 0.42, 1.14 0.72 0.42, 1.21 
Q4 39 (25.7) 2298 (25.0) 0.96 0.53, 1.76 0.94 0.50, 1.77 
Vitamin A, 
RAE (µg) 
      
Q1 49 (32.2) 2295 (25.0) 1  1  
Q2 31 (20.4) 2294 (25.0) 0.67 0.42, 1.06 0.61 0.37, 0.98 
Q3 32 (21.1) 2295 (25.0) 0.72 0.45, 1.16 0.72 0.44, 1.18 
Q4 40 (26.3) 2294 (25.0) 1.00 0.60, 1.67 0.94 0.55, 1.63 
Carotene, 
alpha (µg) 
      
Q1 46 (30.3) 2294 (25.0) 1  1  
Q2 45 (29.6) 2295 (25.0) 0.98 0.65, 1.48 1.09 0.70, 1.68 
Q3 26 (17.1) 2294 (25.0) 0.58 0.35, 0.93 0.58 0.34, 0.99 
Q4 35 (23.0) 2295 (25.0) 0.81 0.51, 1.28 0.87 0.53, 1.45 
Carotene, 
beta (µg) 
      
Q1 42 (27.6) 2294 (25.0) 1  1  
Q2 44 (29.0) 2295 (25.0) 1.06 0.69, 1.63 1.15 0.74, 1.80 
Q3 31 (20.4) 2295 (25.0) 0.77 0.48, 1.23 0.83 0.50, 1.37 
Q4 35 (23.0) 2294 (25.0) 0.91 0.57, 1.46 0.96 0.57, 1.63 
Retinol (µg)       
Q1 41 (27.0) 2295 (25.0) 1  1  
Q2 36 (23.7) 2294 (25.0) 0.93 0.59, 1.47 0.90 0.56, 1.43 
Q3 37 (24.3) 2295 (25.0) 1.01 0.63, 1.61 0.96 0.59, 1.57 
Q4 38 (25.0) 2294 (25.0) 1.16 0.69, 1.95 1.09 0.63, 1.87 
Folate, DFE 
(µg) 
      
Q1 43 (28.3) 2294 (25.0) 1  1  




Q3 35 (23.0) 2294 (25.0) 0.92 0.57, 1.48 0.85 0.52, 1.41 
Q4 39 (25.7) 2295 (25.0) 1.14 0.67, 1.93 1.18 0.69, 2.02 
DQI-P       
Q1 34 (22.5) 2056 (22.6) 1  1  
Q2 47 (31.1) 2206 (24.2) 1.32 0.84, 2.08 1.38  0.87, 2.19 
Q3 37 (24.5) 2334 (25.6) 1.01 0.62, 1.66 1.03 0.61, 1.72 
Q4 33 (21.9) 2522 (27.7) 0.88 0.50, 1.54 0.91 0.49, 1.66 
a Model was adjusted for energy intake (continuous) 
b Model was adjusted for maternal age (continuous), race/ethnicity (categorical), periconceptional vitamin 




Table 4.3 Association between dietary pattern class and having a child with primary congenital 
















Western 40 (26.3) 2300 (25.1) 1  1  
Prudent 46 (30.3) 3024 (33.0) 0.86 0.56, 1.32 0.82 0.52, 1.29 
Mexican 16 (10.5) 1404 (15.3) 0.69 0.38, 1.24 0.80 0.36, 1.78 
Low-Calorie 
Western 
50 (32.9) 2450 (26.7) 1.14 0.75, 1.74 1.04 0.67, 1.64 
a Model was adjusted for energy intake (continuous) 
b Model was adjusted for maternal age (continuous), race/ethnicity (categorical), periconceptional vitamin 




The importance of maternal diet in the etiology of birth defects has been well 
demonstrated22,23,124,125,148. Our study is the first to report on the association between maternal 
nutrition and PCG and ASDs. Our results indicate that higher intake of some nutrients and certain 
dietary patterns may be associated with a lower odds of PCG and ASDs.   No association between 
these defects and the DQI-P were noted. 
 We found consistently lower odds in the top three quartiles of calcium, choline, and vitamin 




implicated to impact the function of trabecular meshwork and retinal ganglion cells151,152. There 
are currently no epidemiologic studies on the association between calcium or vitamin E and 
congenital glaucoma. Deficiencies in vitamin E, a potent lipophilic antioxidant153, during 
pregnancy have been linked to increased fetal demise 154 in animal studies and early miscarriage 
in human studies155. Finally, choline has been studied for its beneficial effects in retinal progenitor 
cell development156. Our study is the first to report on the association between choline intake and 
risk of anterior segment defects of the eye. In contrast to our findings,  a recent study of diet and 
anophthalmia (absence of one or both eyes) and microphthalmia (abnormally small eye(s)) in 
NBDPS observed slightly elevated odds with increasing total choline levels148. The benefits of 
choline may therefore be limited to certain structures of the eye. The human eye is derived from 
various embryonic tissues including the neural ectoderm, surface ectoderm, and mesenchymal 
cells predominantly arising from neural crest cells, the latter contributing substantially to the 
anterior structures. This developmental pattern could explain why higher levels of choline have 
been found to be associated with reduced odds of neural tube defects157.  
There is limited research on the use of vitamin/mineral supplements amongst PCG case 
mothers. Vogt et al111 found a lower odds among mothers that reported use of iron and vitamin D 
supplements during pregnancy. There did not appear to be a consistent pattern among higher 
quartiles of dietary iron intake in the mothers within NBDPS. We did not investigate vitamin D 
intake within our study population. Similar to findings from studies of other birth defects145,157, 
Vogt et al111 found an lower odds of having a child with PCG in their study population among 
mothers who used folic acid supplements during pregnancy. In our study there was a lower odds 
of PCG and ASDs among those in the second and third quartiles compared to the lowest dietary 




ASDs. These findings are similar to previous NBDPS work by our group showing that mothers 
who took periconceptional folic acid-containing  supplements less than once per day or daily had 
increased odds of having a child with PCG (aOR 1.23, 95% CI 0.72-2.10; aOR 1.37, 95% CI 0.73-
2.57)112. These findings may be explained by the differing study periods and when mandatory folic 
acid fortification was implemented in each country. The study period for Vogt et al111 (1980- 2002) 
predated Hungary’s folic acid food fortification program which began in August 1998158, whereas 
the NBDPS study population used in congenital glaucoma analyses (2000-2011) occurred after 
fortification programs were implemented in the United States8.  
We did not find an association between DQI-P and PCG and ASDs in this study. These 
findings differ from literature on more common birth defects like gastroschisis22, orofacial clefts23, 
and neural tube defects23 that found higher diet quality was associated with reduced risk of these 
birth defects. The sample size of cases in each of these studies ranged from nearly two- to ten-
times the number of cases in this analysis and therefore it’s possible that our study was 
underpowered.  
 Studies that have examined dietary patterns in birth defects research have found that 
“healthier diets” (those rich in fruits and vegetables23,145 or specific nutrients like folate and 
choline159) were associated with reduced risks of birth defects. Similarly, we found that those 
mothers who belonged to the Prudent dietary pattern, characterized by greater fruit and vegetable 
intake, had lower odds of having a child with PCG or ASDs. Interestingly, we found similar odds 
ratios among those in the Prudent and Mexican dietary patterns. This may be due to higher levels 
of free radical scavengers or anti-oxidants, which have been shown to modify PCG phenotypes in 




 This study has many strengths. NBDPS is a multi-year, population-based case- control 
study which includes participants from 10 different states. These participants reflect racial/ethnic, 
geographic, and socioeconomic diversity that is generally representative of the US population160. 
Furthermore, methods are rigorous and standardized across centers ensuring thorough and uniform 
data collection. Individuals who chose to participate in the study were not substantially different 
than those who chose not to be interviewed, which further provides support of the 
representativeness of the study sample112. Clinical review and classification of case infants 
provides a rigorously defined case sample for this study. Another strength of this study is the fact 
that maternal diet was measured in various ways. This approach yields a more comprehensive 
analysis of maternal nutrition. Though many epidemiologic studies evaluate the impact of single 
nutrients, this approach does not account for correlations between nutrient intake, nor the complex 
interactions in bioavailability between nutrients. In addition to the individual nutrients, we also 
used a composite score measuring diet quality which allowed for the assessment of food groups 
and incorporates dietary recommendations specific for pregnant women. Lastly, our data-driven 
approach (latent class analysis) identifies empirical dietary patterns inherent within our study 
sample, which allows for exploration of patterns that may not necessarily align with a “gold 
standard” based on recommended intake of specific nutrients or food items.  
Despite the size of NBDPS, the rarity of PCG and ASDs still resulted in a relatively small 
number of cases and imprecise effect estimates. Nonetheless, this national study is the largest to 
examine maternal diet in relation to these birth defects. NBDPS cases are limited to infants 
diagnosed within the first year of life. Although most infants with PCG are diagnosed within the 
first year of life 1, our case sample may be incomplete and could miss milder cases that are not 




reduced access to healthcare). Further, though the FFQ is validated, this study still includes self-
reported data on each mother’s diet in the year before pregnancy. Some foods may be believed to 
be healthier than others, possibly resulting in the potential for differential recall bias between case 
and control mothers. If case mothers are more likely to report some of these foods (e.g. fruits, 
vegetables, whole grains), we would have seen more positive associations for increasing 
micronutrient intake. Finally, as little is known about the risk factors for PCG and ASDs, there 
may be residual confounding. One such possibility is heterogeneity in underlying genetic 
susceptibility. The most consistently mutated gene in congenital glaucoma is CYP1B1, with many 
of the mutations being described in different ethnic populations69. These patients may develop 
congenital glaucoma regardless of non-genetic exposures. Ideally, future studies would account 
for known genetic variants when investigating non-genetic exposures like maternal diet.    
In summary, this study evaluated specific maternal dietary factors, diet patterns, and diet 
quality as risk factors for PCG and ASDs in a large, population-based case-control study. We 
found that higher intake of some nutrients and certain dietary patterns were associated with lower 
odds of PCG and ASDs. These findings, if replicated, add to the accumulating evidence of the 






CHAPTER 5. – EXOME SEQUENCING TO IDENTIFY NOVEL GENES 
UNDERLYING PRIMARY CONGENITAL GLAUCOMA IN THE NATIONAL BIRTH 
DEFECTS PREVENTION STUDY 
5.1 Introduction 
Primary congenital glaucoma (PCG) is diagnosed early in childhood and often occurs 
without overt structural eye defects6. Children present with raised intraocular pressure (IOP), loss 
of corneal transparency, photophobia, and enlargement of the eye2. Raised IOP in this context is 
thought to be a result of reduced flow of aqueous humor out of the anterior chamber of the eye 
through the trabecular meshwork, a porous structure of tissues161.  
In the US the prevalence of PCG is approximately 1 in 10,000 live births per year2,3, but 
has been reported to be as high as 1in 1,250 in communities with high consanguinity 34. 
Historically PCG was considered inherited as an autosomal recessive trait; however,this model 
of inheritance has been recently challenged by reports of transmission in successive generations, 
unequal sex distribution among affected individuals, and lower-than-expected numbers of 
affected siblings in familial cases64,67,68,70–72. 
A few genes are known to be responsible for some cases of PCG, though the most 
commonly mutated gene is is CYP1B1, a cytochrome P450 enzyme. Frequencies of specific 
CYP1B1 mutations are known to vary with reports of  90-100% cases of Slovakian Roma 
Gypsies, 50% of cases from Brazil, 44%  of cases from India, and 20% of cases from Japan 
having CYP1B1 mutations 9,10,162. Despite these high prevalences in some populations, 
pathogenic variants have only been found in 16-25% of families from the US10,163. Mutations in 




PCG, but studies in families from the US have failed to find the same disease-causing 
mutations10. This finding suggests that variants in genes  other than CYP1B1 may cause PCG in 
the general US population.  
In this study, we will describe the prevalence of CYP1B1 variants identified used whole-
exome sequencing data of complete trios (mother, father, and PCG-affected child) from the 
National Birth Defects Prevention Study.,This is a population-based case-control study that has 
been shown to be generally representative of the US population160. In addition, we used these 
data to discover variants in genes which have not previously been linked to PCG cases in the 
current literature.  
5.2 Materials and Methods  
Study Population 
Data for this analysis come from the National Birth Defects Prevention Study (NBDPS), a 
large multicenter population-based case-control study of over 30 major structural birth defects in 
the US. Detailed methods have been reported previously127. Briefly, case infants were identified 
through birth defects surveillance systems in ten states (AR, CA, GA, IA, MA, NJ, NY, NC, TX, 
and UT) and were diagnosed up to one year after delivery. Clinical geneticists at each study center 
reviewed abstracted medical records to confirm that identified cases met eligibility criteria. Cases 
were then systematically reviewed again by a study-wide clinician to perform further classification 
according to study protocols (cite Rasmussen paper). Cases with defects of known etiology, 
including single-gene disorders and chromosomal abnormalities were excluded.  
This analysis only included WES data from PCG cases (ICD-9 codes 743.200-743.204) 




Cases of PCG were eligible for NBDPS from birth years 2000-2011, though all cases included in 
this analysis were enrolled after 2004. 
The NBDPS was approved by the Institutional Review Board (IRB) at the Centers for 
Disease Control and Prevention, and each study center also received local approval.  
Buccal Cell Collection and DNA Isolation 
 Families that participated in the NBDPS completed a telephone interview between 6 
weeks and 18 months after delivery, and were subsequently mailed a buccal cell collection kit 
which included documents for informed consent, 6 cytobrushes (2 per eligible family member), 
instructions for use, and a postage-paid return mailer. DNA was extracted from one of the 
cytobrushes using either a phenol-chloroform method or Gentra Purgene (Qiagen). DNA 
quantity was assessed by quantitative real-time PCR using the human RNaseP gene, and STR 
markers were used to assess DNA quality. Quality control standards included 0.1 ng/uL DNA, 
successful PCR amplification after at least two attempts with at least one STR marker, and 
alleles consistent with the reported family relationship127.   
Whole-exome sequencing and alignment 
 Samples were prepared for sequencing at the NIH Intramural Sequencing Center (NISC) 
using 100 ng of genomic DNA and the Accel-NGS 2S Plus DNA Library Kit. Modifications to 
the library kit protocol included modified PCR cycling conditions to improve recovery of high 
GC regions and swapping a polymerase at the post-capture library amplification step.   
 The Nimblegen SeqCap EZ Exome + UTR Library (Version 3.0) was used for whole-
exome sequencing. Samples were then pooled and sequenced on an Illumina HiSeq 2500 
instrument.  Image analysis and base calling were performed using Illumina Genome Analyzer 




 Sequence reads were aligned to the human reference sequence (NCBI build 37/hg19) 
using the Illumina aligner “ELAND” (Efficient Large-scale Alignment of Nucleotide Databases). 
When at least one read in a pair maps to a unique location in the genome, that read and its pair 
are then subjected to a more accurate alignment with Novoalign v3.02.07.  The aligned lane bam 
files were merged, sorted, and indexed. Sequenced bases with a probability of an incorrect base 
call of 1 in 100143, or a phred quality scores less of than 20, were ignored. 
Identification of Genes 
 The University of Washington Center for Mendelian Genomics reviewed the whole-exome 
sequencing data and pedigree files, and confirmed the sex of all participants and the relationships 
reported within triads. More detailed methods can be found in Jenkins et al164. Briefly, variant 
filtration was conducted under various Mendelian inheritance models using GEMINI 0.20.2165. 
Variant filters included depth ≥ 6, genotype quality of ≥ 20, alternative allele ≤ 0.005 across any 
single population within reference databases (ExAC v0.3166), Exome Sequencing Project 6200 
(v2), 1000 Genomes (phase 3), or the UK10K 2016-02-15 release167), and a predicted medium to 
high impact of the gene/protein. Finally, any variants that did not pass the strand bias filter in 
GEMINI were excluded. To further narrow our focus on genes which could create PCG 
phenotypes, we decided to focus on those which are known to underlie other Mendelian 
conditions with phenotypic overlap, genes with roles in eye development, or those which are in 
the same pathways as genes in which mutations have been reported in PCG cases or other 
anterior segment defects of the eye (e.g. CYP1B1, LTBP2, FOXC1, MYOC, PAX6 or PITX269).  
5.3 Results 
A total of 38 complete trios with a PCG-affected child and unaffected parents underwent 




between the WES samples and all PCG cases that are enrolled within NBDPS that were 
conceived without donor egg or sperm. There were far fewer mothers who identified as Hispanic 
among WES samples. Both maternal and paternal age at delivery were slightly higher among the 
WES samples and there were slight differences in the proportion of samples from each of the 
NBDPS centers.  
There was one discrepancy on the sex of the affected child in one of the families. Due to 
our inability to resolve this through a review of collected clinical and interview data, we 
excluded that family from further analysis, leaving a total sample size of 37 trios. Two families 
had high levels of contamination (freemix=0.035 and 0.09; as described in Jun et al168) and are 
identified as such throughout the rest of this paper.  
 Five of 37 families (13.5%) carried known CYP1B1 variants (Table 1). Each of these 
families had compound heterozygous changes which included variants that have been reported in 
children with PCG previously. There were four frameshift changes, four missense mutations, and 
two stop gain, but only two variants were identified in more than one family. A 13-bp deletion 
(p.Arg355fs) resulting in a pathogenic frameshift change was identified in two of five families 
(both Non-Hispanic White). In addition, a missense mutation (p.Glu387Lys) was identified in 
one Non-Hispanic White and one Non-Hispanic Black family.  In one family, which had no 
suspected pathogenic CYP1B1 variants, the affected child had a de novo frameshift variant 
(c.1141dupG) in FOXC1 which is predicted to leads to an early termination of the amino acid 
sequence. 
 A number of individual families included cases that harbored variants in genes that are 
known to be important in eye development or are known to cause other Mendelian conditions 




were found in CRYBB2, RXRA, GLI2, POU4F1, PIEZO2, and B3GALT6. One homozygous 
recessive variant was found in POMT2. A number of compound heterozygous changes were 
found in ALDH3A2, CREBBP, USH2A, UGT1A8, AND SLC4A11. Information about functional 
changes, whether each variant has been previously identified, and both CADD and PolyPhen 





Table 5.1 Comparison of demographic characteristics of WES samples to all PCG cases within 
NBDPS.   
Demographic Characteristics 
All PCG cases 
(n=136) 
WES PCG samples 
(n=38) 
Maternal Race/Ethnicity   
Non-Hispanic White 63 (46.3) 23 (60.6) 
Non-Hispanic Black 31 (22.8) 9 (23.7) 
Hispanic 32 (23.5) 2 (5.3) 
Asian/Pacific Islander 7 (5.2) 2 (5.3) 
Other 3 (2.2) 2 (5.3) 
Maternal Age at Delivery   
<=24 53 (39.0) 9 (23.7) 
25-34 71 (52.2) 25 (65.8) 
>=35 12 (8.8) 4 (10.5) 
Paternal Age At Delivery   
<=24 31 (24.0) 7 (18.9) 
25-34 67 (51.9) 21 (56.8) 
>=35 31 (24.0) 9 (24.3) 
Study Center   
Arkansas 22 (16.2) 5 (13.2) 
California 14 (10.3) 2 (5.3) 
Iowa 12 (8.8) 4 (10.5) 
Massachusetts 19 (20.0) 6 (15.8) 
New Jersey 1 (0.7)  
New York 8 (5.9) 2 (5.3) 
Texas 11 (8.1) 1 (2.6) 
CDC/Atlanta 27 (19.9) 9 )23.7) 
North Carolina 5 (3.7) 1 (2.6) 



















































































































































De novo GLAUC_B1_7 CRYBB2 Missense p.Trp59Arg  21.8 Probably 
Damaging 
 GLAUC_B1_9 RXRA Stop Gain c.1101_1102ins*  - Unknown 
 GLAUC_B1_27ǂ GLI2 Missense p.Ala1398Thr rs768730033 10.2 Benign 
 GLAUC_B1_32 POU4F1 In-frame 
Deletion 
c.237_239delGCC  - Unknown 
 GLAUC_B1_34 PIEZO2 Missense p.Ile1441Val  14.3 Probably 
Damaging 




GLAUC_B1_30 POMT2 Missense p.Arg659Gln rs770606360 34 Probably 
Damaging 






To date, most of the published literature on genetic risk factors for PCG has included reports on 
mutations within CYP1B1, LTBP2, FOXC1, and MYOC. Consistent with previous studies10, we 
show in our sample that CYP1B1 is likely the main causative gene for primary congenital 
glaucoma in some families, but that mutations in this gene are less common among cases from 
the US (13.5%) than have been previously reported in other populations. We also identified one 
family which had a mutation in FOXC1, which has previously been implicated in primary 
congenital glaucoma patients169. It has previously been suggested that there may be other, novel 
genes which cause primary congenital glaucoma in more ethnically heterogeneous populations. 
We have included variants in a number of genes which have not previously been investigated in 
association with primary congenital glaucoma, but which are known to be important in eye 
development or are known to cause Mendelian conditions with phenotypic overlap.  
CRYBB2 variant 
 The CRYBB2 gene encodes beta–crystallins which are major proteins of the vertebrate 
lens and are important for maintaining the transparency and refractory index of the lens. The 
specific variant (p.Trp59Arg) that we found has not been previously described, though is 
expected to be pathogenic by PolyPhen and CADD. It occurs in exon 4 near the conversion of a 
β-sheet to a α-helix. A similar variant (p.Trp59Cys) has been described in congenital cataracts, a 
condition where the lens becomes opaque. This area of the protein has been previously shown to 
be important in correct protein folding170.  
CREBBP variant 
 During eye development, the CREBBP gene is upregulated along with αA-crystallins as 





acetyltransferase activity allowing for transcriptional activation172, and it can also act as a sort of 
scaffold to stabilize proteins of the transcription complex173. Mutations in CREBBP have been 
linked to Rubinstein-Taybi syndrome (RSTS) which is characterized by distinctive dysmorphic 
features, short stature, and moderate to severe intellectual disability174,175. A recent report by 
Menke et al175 described a number of patients who had missense mutations in a specific region of 
CREBBP who did not exhibit the typical phenotypes of RSTS patients. Interestingly, in the last 
there 50 years, there have been two reports of glaucoma in children diagnosed with RSTS; one 
with juvenile glaucoma176 and one with congenital glaucoma177. 
SLC4A11 variant 
There are multiple molecular actions proposed for the SLC4A11 protein, including a 
number of different ion channels and potential aquaporin activities178. Studies have shown that 
SLC4A11 is present in the corneal endothelium, however there are no reports of expression in the 
trabecular meshwork or aqueous outflow pathways178. Dysfunction in this gene has been strongly 
linked to congenital hereditary endothelial dystrophy (CHED), a rare disorder of the corneal 
endothelium in which opacification of the cornea may be present at birth178. There are only a few 
published case reports of glaucoma in patients diagnosed with CHED178,179. Alsaif et al180 
recently published whole exome sequencing results of CYP1B1-negative cases of children from 
Saudi Arabia where they reported one family with a SLC4A11 mutation which they determined 
had been misdiagnosed as primary congenital glaucoma.  
POMT2 variant 
 The protein encoded by POMT2 is part of the O-mannosyltransferase (POMT) enzyme 
complex which plays a role in glycosylation of α-dystroglycan. It is particularly present in the 





(p.Arg659Gln) has been listed in ExAC Browser181 with an allele frequency of 1.65 x 10-5. 
Variants in POMT2 have been reported in individuals affected by Walker-Warburg syndrome, or 
congenital muscular dystrophies that affect the muscles, brain, and anterior portion of the 
eyes182,183. Eye abnormalities include microphthalmia (small eyes), buphthalmos (enlarged eyes), 
cataracts, and problems with the optic nerve184. The POMT2 protein is made up of 750 amino 
acids. The homozygous recessive missense variant in this study results in an amino acid change 
from a positively charged amino acid (Arg) to a polar amino acid (Gln) at position 659.  
B3GALT6 variant 
 B3GALT6 encodes for an enzyme involved in biosynthesis of glycosaminoglycans 
(GAG) which are long chains of unbranched polysaccharides with a repeating disaccharide unit 
that are the most abundant heteropolysaccharide in the human eye185. GAGs are important for 
their ability to fill in space, including in the extracellular matrix between cells, and to organize 
water molecules. They also make up a portion of the cornea, where the transparency is due to 
uniform distribution of collagen fibrils which are regulated by proteoglycans186,187. Human 
studies have GAGs play an important role in age-related diseases of the cornea185. B3GALT6 
mutations have been reported in spondyloepimetaphyseal dysplasia (SEMD), a group of skeletal 
disorders, some of which show mild craniofacial dysmorphism including prominent eyes188. 
There have not been any reports of variants in B3GALT6 in congenital glaucoma cases. The 
missense variant identified in our study (p.Thr266Phe) results in an amino acid change in exon 
X; the protein has 329 amino acids.   
PIEZO2 variant 
 This gene encodes a large mechanically-activated cation channel with more than thirty 





Syndrome and Distal Arthrogryposis Type 3, both of which may present with ocular 
abnormalities. A recent study of 14 patients with microphthalmia and/or anophthalmia identified 
one with a missense variant in PIEZO2190. Similarly, we found a missense mutation resulting in 
an amino acid change (p.Ile1441Val) occurring approximately halfway through this large 
protein, which is predicted to be damaging even though both amino acids are hydrophobic.  
RXRA variant 
 Retinoic acid, a metabolite of vitamin A, serves as a signaling molecule during 
embryonic development of a number of tissues including the eye191. Retinoic acid receptor alpha 
(RXRA) is a receptor located in the nucleus that can mediate the biological effects of retinoids191. 
Exposure to retinoids, like isotretinoin, early in pregnancy have been implicated with a spectrum 
of neural crest-related phenotypes including craniofacial malformations and malformations of the 
CNS192. The biological mechanism behind these defects may overlap with ocular defects. AFor 
example, a number of variants near RXRA193 have been associated with central corneal thickness, 
which have been shown to be lower in glaucoma patients than the general population. This 
suggests that variants near RXRA can cause ocular phenotypes. The variant found in our study 
includes an insertion that results in an early termination and a truncation of the RXRA protein. 
Stop gain variants are of particular interest because they can have potentially profound impacts 
on protein structure194.  
GLI2 variant 
GLI2 encodes a C2H2-type zinc finger which has the ability to act as a mediator of Sonic 
hedgehog (shh) signaling which is important in embryonic development. Mutations in this gene 
have been found in patients with holoprosencephaly-like features195. Holoprosencephaly (HPE) 





the eye and forebrain195,196. The variant found in this study resulted in an amino acid change 
from a hydrophobic to an uncharged amino acid toward the end of this protein. PolyPhen-2 
predicted this would result in a benign change and the CADD score (CADD= 10.2) indicated that 
this would be a likely benign change.  
POU4F1 variant 
 The POU4F1 gene encodes a member of the POU-IV class of neural transcription factors 
that are expressed in a subset of retinal ganglion cells197–199. Currently, there have not been any 
reports of mutations in POU4F1 and congenital eye defects. This gene was selected because it is 
important in retinal ganglion cell survival, cell fate, and axonal targeting during development199. 
CADD scores and PolyPhen-2 are not calculated for deletions, like the one found in this sample, 
though the deletion occurs early in the protein (base 237 of 5,199 bases). 
ALDH3A2 variant 
 The ALDH2A2 gene is a member of the aldehyde dehydrogenase family which catalyze 
the conversion of fatty aldehydes with medium- to very-long-chain fatty acids. According to the 
Human Protein Atlas200, ALDH3A2 is not expressed in the eye but is present in a number of other 
tissues. This gene is frequently mutated in another Mendelian condition called Sjogren-Larsson 
Syndrome in which patients present with mental retardation, spastic di- or tetraplegia, and 
ichthyosis201. The variants discovered in this population were both missense variants that were 
inherited in a compound heterozygote manner, with one variant predicted to be possibly 
damaging and another thought to be benign. 
USH2A variant 
 USH2A encodes for a basement membrane protein called usherin which is present in the 





can include retinitis pigmentosa (RP), an eye condition that can result in gradual vision 
loss202,203. Although vision loss is reported in both PCG and patients with RP, the age at onset for 
visual loss in RP patients isn’t until approximately 10 years of age204. The compound 
heterozygote variants identified in our sample include both a frameshift and a missense variants 
that result in an amino acid change. The frameshift variant results in an amino acid change from 
a threonine to a proline which have different structures and chemical properties.  
UGT1A8 variant 
 UGT1A8 encodes an enzyme that is part of the glucuronidation pathway that transforms 
small lipophilic molecules like steroids, hormones, and water-soluble, excretable metabolites205. 
It is associated with other drug metabolism pathways that include cytochrome P450 enzymes (if 
which CYP1B1 belongs) and is mostly expressed in hepatic cells205,206. Most of the literature 
describing conditions associated with this gene are in phenotypes that include conditions of the 
gastrointestinal tract and the liver, such as pericholangitis205 and Gilbert syndrome207. The 
variants identified in this population are both missense variants. The variant that occurs in 
approximately the middle of the protein (p.Ala360Val) is predicted to be potentially damaging, 
whereas the other occurs at amino acid 505 of 530 and is thought to be benign. 
Conclusions 
  There are many strengths to this study, most of which are related to the design of NBDPS 
which is a multi-year, population-based case-control study which includes participants from 10 
different states. These participants reflect racial/ethnic, geographic, and socioeconomic diversity 
that has been shown to be generally representative of the US population160. Furthermore, 
methods are rigorous and standardized across centers ensuring thorough and uniform data 





those who chose not to be interviewed, which further provides support of the representativeness 
of the study sample112. Clinical review and classification of case infants provides a rigorously 
defined case sample. This study also benefited from the availability of WES over more 
traditional genotyping methods that are often used in epidemiological studies. This is an 
important strength of this paper since genotyping requires a priori hypotheses about important 
genes, important areas of the genome, or are chosen because of their availability on already 
validated arrays that are commercially available. Much like the strengths of genome-wide 
association studies (GWAS)208, WES allows for a comprehensive scan of the the exome in a less 
biased way to identify important and novel factorsFurther, in this analysis we had WES available 
from complete trios which allows for high confidence in the inheritance patterns of each of these 
variants and likely fewer false positive results.   
There are some limitations of this study. NBDPS is one of the largest studies of birth 
defects in the United States, though cases are limited to infants diagnosed within the first year of 
life. Although close to 80% of infants with PCG are diagnosed within the first year of life1, this 
means that our case sample might miss close to 20% of cases. Those missing may include milder 
cases that are not diagnosed until after one year of age or those who are diagnosed later for other 
reasons (e.g., reduced access to healthcare). Despite a few reports209,210 in the literature of PCG 
cases being inherited in an autosomal dominant manner, we did not investigate this inheritance 
pattern in the current analysis. Finally, we did not attempt to replicate these findings in another 
study sample at this time. Though finding the variants identified within this study in other 
families would lead to an increased confidence in their importance and thus lead to a higher 





families and difficult to replicate without other large studies with WES findings of which there 
are few in the United States.  
In conclusion, this study confirms previous findings that, although CYP1B1 is the main 
causative gene for primary congenital glaucoma in some families and that the prevalence of 
mutations is less common in the US compared to other populations. We identified a number of 
variants in other genes which have not previously been investigated in association with primary 
congenital glaucoma but are known to underly other Mendelian conditions with phenotypic 
overlap or are important in eye development, and have detected mutations that appear to have 
functional consequences. Additionally, many of the proteins encoded by these genes play 
important roles in eye deveelopment. Future studies are needed to replicate these findings in 
cohorts of patients without mutations in known disease-causing genes. Experimental studies to 







CHAPTER 6. – DISCUSSION AND CONCLUSIONS 
6.1 Summary of Specific Aims 
 There are few epidemiologic studies that have evaluated risk factors for PCG and ASDs. 
Of the studies that are available, many have occurred in populations with limited generalizability 
to the United States.  
 In Aim 1 we evaluated the association between maternal dietary factors and PCG and 
ASDs. We estimated associations between intake of specific micronutrients and a measure of 
diet quality (DQI-P score). Additionally, we used latent class analysis to categorize women into 
dietary patterns and evaluated whether associations were present between specific dietary 
patterns and PCG and ASDs. 
 In Aim 2, we used whole-exome sequencing of a subset of PCG cases to describe the 
genetic variation in a US-based population. Complete family trios allowed for evaluation of a 
variety of inheritance patterns. We assessed the prevalence of pathogenic CYP1B1 variants and 
described variants in genes which hadn’t previously been linked to PCG.  
6.1.1 Aim 1 
 Among individual micronutrients, few odds ratios were statistically significant and most 
were not monotonic across quartiles. However, we found some inverse, yet imprecise, 
associations with increasing intake. For example, compared to the lowest quartile of intake, all 
three quartiles of calcium, choline, and vitamin E were associated with consistently lower odds. 





increased odds among those in the highest. Both zinc and vitamin A were suggestive of this U-
shaped pattern, though aORs in the highest quartile compared to the lowest quartile showed 
values close tothe null value. There did not appear to be any association between DQI-P score 
and having a child with PCG or ASDs. 
 Using latent class analysis we were able to identify the same four dietary patterns as 
previous NBDPS studies. Those mothers who belonged to the Prudent and Mexican dietary 
patterns had weakly lower odds ratios compared to mothers in the Western dietary pattern. Mothers 
in the Low-Calorie Western dietary pattern had similar odds compared to those in the Western 
dietary pattern. 
6.1.2 Aim 2 
 Similar to previous work, CYP1B1 was found to be the main causative gene for primary 
congenital glaucoma in our sample, though the overall prevalence was low (13.5%) relative to 
other studies. All of the CYP1B1 mutations present in our population had been reported before. 
One of the families harbored a de novo variant in the FOXC1 gene, a gene which has previously 
been linked to PCG and ASDs. In families that had no CYP1B1 mutations, there were variants 
which were predicted to result in moderate-to-severe functional changes in a number of genes 
which have not previously been investigated in association with primary congenital glaucoma 
but are known to underlie other Mendelian conditions with potential phenotypic overlap or are 
known to be involved in eye development. De novo variants were found in CRYBB2, RXRA, 
GLI2, POU4F1, PIEZO2, and B3GALT6, one homozygous recessive variant was found in 
POMT2, and compound heterozygous changes were found in ALDH3A2, CREBBP, USH2A, 





6.2 Strengths and Limitations 
6.2.1 Strengths 
A major strength of this study is the use of the NBDPS study population. NBDPS is a 
multi-year, population-based case control study which includes participants from 10 different 
states. This large sample size is required for rare outcomes like PCG and ASDs. These 
participants show diversity on a number of scales including various racial/ethnic groups, 
geographic locations, and socioeconomic status. Methods are rigorous and standardized across 
centers ensuring thorough and uniform data collection on a number of relevant covariates. 
Clinical review and classification of case infants provide a rigorously defined case sample for 
this study. In addition, there are no other US-based studies of PCG and ASDs of this size and 
scope.  
In the analysis for Aim 1, we were able to comprehensively evaluate maternal diet using 
a variety of measures. Not only did we evaluate individual micronutrient level information, we 
were able to evaluate a composite score of more than one nutrient at a time which also 
incorporated dietary recommendations for pregnant women. Similarly, we utilized a data-driven 
approach which allows for interactions between multiple nutrients, but doesn’t measure against a 
prevailing hypothesis of what defines quality foods. 
One of the major strengths of Aim 2 is that whole-exome sequencing data was used to evaluate 
genetic variation in these individuals. Candidate gene and GWAS approaches, which are often 
used in large epidemiologic studies of birth defects, require researchers to have a prior hypothesis 
about specific genes, and regions of genes, to investigate. Whole-exome sequencing does not 
require this, and allows for an evaluation of all of the protein coding (exonic) regions of the 





control measures, underwent whole-exome sequencing. This allowed for high confidence in the 
inheritance patterns because we have the genomic sequence of each unaffected parent. We chose 
to focus on variants that were predicted to have a medium-to-high functional impact on the protein 
based on multiple software sources (CADD-scores, PolyPhen, etc). 
6.2.2 Limitations  
Despite the size of NBDPS, the rarity of PCG and ASDs still result in a relatively small 
number of cases and imprecise effect estimates. In addition, NBDPS cases are limited to infants 
diagnosed within the first year of life. Although approximately 80% of PCG infants are diagnosed 
within the first year of life1, our case sample may be incomplete and could include infants with 
more severe forms or those who are diagnosed early for other reasons (e.g., better access to 
healthcare). Finally, as such little is known about the risk factors for PCG and ASDs, there may 
be unmeasured confounding. This may further be complicated by heterogeneity in underlying 
genetic susceptibility. The most consistently mutated gene in congenital glaucoma is CYP1B1, 
with many of the mutations being described in different ethnic populations69. These patients may 
develop congenital glaucoma regardless of non-genetic exposures. Ideally, future studies should 
evaluate potential modification by variant/gene status when investigating non-genetic exposures 
like maternal diet. This should be a high priority for researchers.     
Specific to Aim 1, the FFQ is a validated measure of dietary intake, however this study still 
includes self-reported data on each mother’s diet in the year before pregnancy. Due to the period 
of time between the maternal interview and the time period of interest, there is the possibility of 
misclassification for specific foods and/or micronutrients. Further, some foods may be believed to 
be healthier than others, potentially resulting in differential recall bias between case and control 





vegetables, whole grains), we would have seen more associations above one for increasing 
micronutrient intake than what we observed. We also chose to combine both PCG and ASD case 
groups for Aim 1 because of the suggestion of a shared etiology and to improve our power to 
observe associations. Despite sub-analyses which split case groups apart and showed similar 
patterns in association measures, there is a possibility that we did not have the precision in these 
small individual case groups to detect different associations between the groups.  
Despite having whole-exome sequencing data on complete trios, we were further limited 
when looking for rare variants in a subset (n=38) of PCG cases from NBDPS in Aim 2. While this 
is one of the larger studies of whole-exome sequencing data from complete families of PCG cases, 
we found a number of variants that were only present in individual families. In addition, in this 
study we only focused on variants that would have been inherited assuming a compound 
heterozygote, de novo, or autosomal recessive pattern. X-linked de novo and X-linked recessive 
patterns were also investigated but did not identify any genes that were known to underlie a 
Mendelian condition with potential phenotypic overlap or were known to be important in eye 
development. Autosomal dominant inheritance patterns have been reported in PCG210 but were not 
investigated in this analysis. Using the same statistical methods to prioritize variants outlined in 
Aim 2, all dominant alleles inherited from either parent would be identified for further 
investigation which would likely result in a large number of false positive variants.  
6.3 Public Health Implications and Future Studies 
6.3.1 Public Health Impact 
 There is very little work on the risk factors for PCG and ASDs in a racially, ethnically, and 
geographically diverse population like that in the United States. Our findings from Aim 1 add to 





Aim 2 where we restricted to only PCG cases, we identified some novel genes which previously 
have not been investigated for their role in PCG. These discoveries may improve the accuracy of 
risk assessment information, identify potential therapeutic targets, and provide information about 
the biological mechanisms underlying this birth defect. 
6.3.2 Future Studies  
There are multiple directions for further research in both Aims of this project. This is the 
first report of the association between maternal diet and PCG and ASD, therefore other studies 
are needed to replicate these findings. Larger studies with more cases, or meta-analytic methods 
to combine estimates from multiple studies, will allow for more precise estimates of association. 
In addition, future studies could attempt to explore new methods of measuring food intake or 
better quantify bioavailability and/or metabolism of individual micronutrients, especially those 
that would translate into large, case-control studies. Other studies which have whole-exome 
sequencing data of patients without disease-causing mutations should replicate the findings of in 
Aim 2. In addition, experimental studies to explore the mechanisms associated with the new 
variants we reported, or evaluating the role of these specific genes, are also warranted. In silico 
functional studies, tissue culture studies, and proteomics, similar to the evaluation of TEK 
variants in Souma et al210, could be employed. The CRISPR-Cas 9 system211 could be used to 
recreate these variants in animal models which could then be evaluated for phenotypic 
similarities with PCG cases.     
6.4 Conclusions 
 In conclusion, this study was able to determine that increasing amounts of specific 
micronutrients and a Prudent or Mexican dietary pattern may be associated with a decreased odds 





and ASDs, other investigations are needed to replicate these findings.  However, these findings, 
along with previous research, support the continued recommendation of diets high in fruits and 
vegetables, like the Prudent and Mexican dietary patterns, among pregnant women. We found that 
CYP1B1 was the most commonly mutated gene among PCG cases in our population, but the 
overall prevalence was low. We also identified a number of other genes which may be etiologically 
relevant in PCG cases from the United States. Other studies which have individuals without known 








APPENDIX 1. SUPPLEMENTARY TABLES FOR CHAPTER 4 
Supplemental Table 1. ORs and 95% CIs for individual nutrients for combined primary 
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